[1] World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF consultation. Geneva, 2006

[2] World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Geneva, 1999

[3] Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом/Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. - 10-й выпуск. Сахарный диабет. 2021; 24 (S1). doi: 10.14341/DM12802

[4] Дедов И.И., Шестакова М.В. Сахарный диабет типа 2: от теории к практике. МИА, 2016

[5] Schwartz SS, Epstein S, Corkey BE, et al. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the Classification Schema. Diabetes Care. 2016; 39(2): 179 - 186. doi: 10.2337/dc15-1585

[6] International Diabetes Federation. IDF Diabetes Atlas. 10th ed. 2021

[7] Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016; 19(2): 104 - 112. doi: 10.14341/DM2004116-17

[8] World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detted in pregnancy. Geneva, 2013

[9] World Health Organization. Classification of diabetes mellitus. World Health Organization. 2019

[10] American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45 (Supplement_1): S17 - S38. doi: 10.2337/dc22-S002

[11] World Health Organization, International Diabetes Federation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. Geneva, http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/index.html (2006)

[12] World Health Organization. Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. Geneva, 2011

[13] International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care. 2009; 32(7): 1327 - 1334. doi: 10.2337/dc09-9033

[14] Дедов И.И., Шестакова М.В. Сахарный диабет: диагностика, лечение, профилактика. Москва: МИА, 2011

[15] Umpierrez G, Korytkowski M. Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016; 12(4): 222 - 232. doi: 10.1038/nrendo.2016.15

[16] E, Corte Z, M, et al. Systematic review of the biological variation data for diabetes related analytes. Clin Chim Acta. 2019; 48861 - 67. doi: 10.1016/j.cca.2018.10.031

[17] Leighton E, Sainsbury CA, Jones GC. A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther. 2017; 8(3): 475 - 487. doi: 10.1007/s13300-017-0265-4

[18] Силко Ю.В., Никонова Т.В., Иванова О.Н., и др. Латентный аутоиммунный диабет взрослых: информативность аутоантител. Терапевтический архив (архив до 2018 г). 2016; 88(10): 42 - 45. doi: 10.17116/terarkh2016881042-45

[19] Sosenko JM, Skyler JS, Palmer JP, et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care. 2013; 36(9): 2615 - 2620. doi: 10.2337/dc13-0425

[20] Shields BM, Hicks S, Shepherd MH, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010; 53(12): 2504 - 2508. doi: 10.1007/s00125-010-1799-4

[21] Shepherd M, Sparkes AC, Hattersley AT. Genetic testing in maturity onset diabetes of the young (MODY): a new challenge for the diabetic clinic. Pract Diabetes Int. 2001; 18(1): 16 - 21. doi: 10.1002/pdi.108

[22] American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45 (Supplement_1): S46 - S59. doi: 10.2337/dc22-S004

[23] National Kidney Foundation. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013; 3(1): 1 - 150.

[24] International Council of Ophthalmology. ICO Guidelines for Diabetic Eye Care. San Francisco, http://www.icoph.org/downloads/ICOGuidelinesforDiabeticEyeCare.pdf (2017)

[25] Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(3): 412 - 418. doi: 10.2337/dc16-2641

[26] Canadian Ophthalmological Society Diabetic Retinopathy Clinical Practice Guideline Expert Committee, Hooper P, Boucher MC, et al. Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Diabetic Retinopathy - executive summary. Can J Ophthalmol. 2012; 47(2): 91 - 101. doi: 10.1016/j.jcjo.2012.01.022

[27] Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. VII. Diabetic nonproliferative retinal lesions. Ophthalmology. 1987; 94(11): 1389 - 1400. doi: 10.1016/s0161-6420(87)33275-0

[28] Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol. 1989; 107(2): 244 - 249. doi: 10.1001/archopht.1989.01070010250031

[29] Public Health England. NHS diabetic eye screening (DES) programme, https://www.gov.uk/topic/population-screening-programmes/diabetic-eye

[30] NHS Scotland National Diabetes Retinopathy Screening, https://www.ndrs.scot.nhs.uk/Links/index.htm/

[31] American Diabetes Association. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45 (Supplement_1): S185 - S194. doi: 10.2337/dc22-S012

[32] Boulton AJM, Malik RA, Arezzo JC, et al. Diabetic Somatic Neuropathies. Diabetes Care. 2004; 27(6): 1458 - 1486. doi: 10.2337/diacare.27.6.1458

[33] England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: A definition for clinical research: Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005; 64(2): 199 - 207. doi: 10.1212/01.WNL.0000149522.32823.EA

[34] Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016; 63(2): 3S - 21S. doi: 10.1016/j.jvs.2015.10.003

[35] Hart T, Milner R, Cifu A. Management of a Diabetic Foot. JAMA. 2017; 318(14): 1387 - 1388. doi: 10.1001/jama.2017.11700

[36] P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016; 59(11): 2298 - 2307. doi: 10.1007/s00125-016-4065-6

[37] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131): 854 - 865.

[38] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131): 837 - 853.

[39] Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24): 2545 - 2559. doi: 10.1056/NEJMoa0802743

[40] Duckworth W, Abraira C, Moritz T, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009; 360(2): 129 - 139. doi: 10.1056/NEJMoa0808431

[41] ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24): 2560 - 2572. doi: 10.1056/NEJMoa0802987

[42] Skyler JS, Bergenstal R, Bonow RO, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology. Diabetes Care. 2009; 32(1): 187 - 192. doi: 10.2337/dc08-9026

[43] Дедов И.И., Шестакова М.В., Аметов А.С., и др. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа. Сахарный диабет. 2011; 14(4): 6 - 17. doi: 10.14341/2072-0351-5810

[44] Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55(6): 1577 - 1596. doi: 10.1007/s00125-012-2534-0

[45] Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care. 2016; 39(7): 1089 - 1100. doi: 10.2337/dc16-0024

[46] American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45 (Supplement_1): S83 - S96. doi: 10.2337/dc22-S006

[47] Nathan DM, Kuenen J, Borg R, et al. Translating the A1C Assay Into Estimated Average Glucose Values. Diabetes Care. 2008; 31(8): 1473 - 1478. doi: 10.2337/dc08-0545

[48] Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019; 42(8): 1593 - 1603. doi: 10.2337/dci19-0028

[49] Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019; 42(3): 400 - 405. doi: 10.2337/dc18-1444

[50] Beck RW, Bergenstal RM, Cheng P, et al. The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c. J Diabetes Sci Technol. 2019; 13(4): 614 - 626. doi: 10.1177/1932296818822496

[51] Vigersky RA, McMahon C. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. Diabetes Technol Ther. 2019; 21(2): 81 - 85. doi: 10.1089/dia.2018.0310

[52] American Diabetes Association. Introduction: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45 (Supplement_1): S1 - S2. doi: 10.2337/dc22-Sint

[53] Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435): 685 - 696. doi: 10.1016/S0140-6736(04)16895-5

[54] Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371(9607): 117 - 125. doi: 10.1016/S0140-6736(08)60104-X

[55] Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493): 1267 - 1278. doi: 10.1016/S0140-6736(05)67394-1

[56] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019; 73(24): e285 - e350. doi: 10.1016/j.jacc.2018.11.003

[57] Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385(9976): 1397 - 1405. doi: 10.1016/S0140-6736(14)61368-4

[58] Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670 - 1681. doi: 10.1016/S0140-6736(10)61350-5

[59] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111 - 188. doi: 10.1093/eurheartj/ehz455

[60] ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15): 1547 - 1559. doi: 10.1056/NEJMoa0801317

[61] Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. J Hypertens. 2017; 35(5): 922 - 944. doi: 10.1097/HJH.0000000000001276

[62] Grenier J, Goodman SG, Leiter LA, et al. Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. Can J Diabetes. 2018; 42(2): 130 - 137. doi: 10.1016/j.jcjd.2017.01.005

[63] ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17): 1575 - 1585. doi: 10.1056/NEJMoa1001286

[64] ГОСТ Р ИСО 15197-2015 Тест-системы для диагностики in vitro. Требования к системам мониторинга глюкозы в крови для самоконтроля при лечении сахарного диабета. Москва: Стандартинформ, 2015

[65] Holman RR, Paul SK, Bethel MA, et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008; 359(15): 1577 - 1589. doi: 10.1056/NEJMoa0806470

[66] Sheppard P, Bending J, Huber J. Pre- and post-prandial capillary glucose self-monitoring achieves better glycaemic control than pre-prandial only monitoring. Pract Diabetes Int. 2005; 22(1): 15 - 22. doi: 10.1002/pdi.733

[67] Boutati EI, Raptis SA. Self-Monitoring of Blood Glucose as Part of the Integral Care of Type 2 Diabetes. Diabetes Care. 2009; 32(suppl_2): S205 - S210. doi: 10.2337/dc09-S312

[68] Harris MI. Frequency of Blood Glucose Monitoring in Relation to Glycemic Control in Patients With Type 2 Diabetes. Diabetes Care. 2001; 24(6): 979 - 982. doi: 10.2337/diacare.24.6.979

[69] Coster S, Gulliford MC, Seed PT, et al. Self-monitoring in Type 2 diabetes mellitus: a meta-analysis. Diabet Med. 2000; 17(11): 755 - 761.

[70] Welschen LMC, Bloemendal E, Nijpels G, et al. Self-Monitoring of Blood Glucose in Patients With Type 2 Diabetes Who Are Not Using Insulin: A systematic review. Diabetes Care. 2005; 28(6): 1510 - 1517. doi: 10.2337/diacare.28.6.1510

[71] Davidson MB, Castellanos M, Kain D, et al. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: A blinded, randomized trial. Am J Med. 2005; 118(4): 422 - 425. doi: 10.1016/j.amjmed.2004.12.006

[72] Davis WA, Bruce DG, Davis TME. Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study. Diabetologia. 2007; 50(3): 510 - 515. doi: 10.1007/s00125-006-0581-0

[73] Farmer A, Wade A, Goyder E, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ. 2007; 335(7611): 132. doi: 10.1136/bmj.39247.447431.BE

[74] Allemann S, Houriet C, Diem P, et al. Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis. Curr Med Res Opin. 2009; 25(12): 2903 - 2913. doi: 10.1185/03007990903364665

[75] Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin. 2006; 22(4): 671 - 681. doi: 10.1185/030079906X96308

[76] McGeoch G, Derry S, Moore RA. Self-monitoring of blood glucose in type-2 diabetes: what is the evidence? Diabetes Metab Res Rev. 2007; 23(6): 423 - 440. doi: 10.1002/dmrr.749

[77] Poolsup N, Suksomboon N, Rattanasookchit S. Meta-Analysis of the Benefits of Self-Monitoring of Blood Glucose on Glycemic Control in Type 2 Diabetes Patients: An Update. Diabetes Technol Ther. 2009; 11(12): 775 - 784. doi: 10.1089/dia.2009.0091

[78] St John A, Davis WA, Price CP, et al. The value of self-monitoring of blood glucose: a review of recent evidence. J Diabetes Complications. 2010; 24(2): 129 - 141. doi: 10.1016/j.jdiacomp.2009.01.002

[79] Towfigh A, Romanova M, Weinreb JE, et al. Self-monitoring of blood glucose levels in patients with type 2 diabetes mellitus not taking insulin: a meta-analysis. Am J Manag Care. 2008; 14(7): 468 - 475.

[80] Ham P. Glycemic control in the hospital: what to do when experts disagree. Am Fam Physician. 2010; 81(9): 1078.

[81] Lewandrowski K. Point-of-care testing: an overview and a look to the future (circa 2009, United States). Clin Lab Med. 2009; 29(3): 421 - 432. doi: 10.1016/j.cll.2009.06.015

[82] Klonoff DC, Perz JF. Assisted Monitoring of Blood Glucose: Special Safety Needs for a New Paradigm in Testing Glucose. J Diabetes Sci Technol. 2010; 4(5): 1027 - 1031. doi: 10.1177/193229681000400501

[83] World Health Organization. WHO injection safety. Fact sheet No. 231. Revised May 2016. Geneva, 2016

[84] Thompson ND, Perz JF. Eliminating the blood: ongoing outbreaks of hepatitis B virus infection and the need for innovative glucose monitoring technologies. J Diabetes Sci Technol. 2009; 3(2): 283 - 288. doi: 10.1177/193229680900300208

[85] Jovanovic L, Savas H, Mehta M, et al. Frequent Monitoring of A1C During Pregnancy as a Treatment Tool to Guide Therapy. Diabetes Care. 2011; 34(1): 53 - 54. doi: 10.2337/dc10-1455

[86] Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002; 48(3): 436 - 472.

[87] American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, et al. Consensus statement on the worldwide standardisation of the HbA1c measurement. Diabetologia. 2007; 50(10): 2042 - 2043. doi: 10.1007/s00125-007-0789-7

[88] Driskell OJ, Holland D, Waldron JL, et al. Reduced Testing Frequency for Glycated Hemoglobin, HbA 1c, Is Associated With Deteriorating Diabetes Control. Diabetes Care. 2014; 37(10): 2731 - 2737. doi: 10.2337/dc14-0297

[89] Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the Inte. Diabetes Care. 2007; 30(9): 2399 - 2400. doi: 10.2337/dc07-9925

[90] Sacks DB. Measurement of Hemoglobin A1c: A new twist on the path to harmony. Diabetes Care. 2012; 35(12): 2674 - 2680. doi: 10.2337/dc12-1348

[91] Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017; 40(12): 1631 - 1640. doi: 10.2337/dc17-1600

[92] Haak T, Hanaire H, Ajjan R, et al. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. Diabetes Ther. 2017; 8(1): 55 - 73. doi: 10.1007/s13300-016-0223-6

[93] Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Ann Intern Med. 2017; 167(6): 365 - 374. doi: 10.7326/M16-2855

[94] Carlson AL, Mullen DM, Bergenstal RM. Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes. Diabetes Technol Ther. 2017; 19(S2): S4 - S11. doi: 10.1089/dia.2017.0024

[95] Ajjan RA, Cummings MH, Jennings P, et al. Optimising use of rate-of-change trend arrows for insulin dosing decisions using the FreeStyle Libre flash glucose monitoring system. Diabetes Vasc Dis Res. 2019; 16(1): 3 - 12. doi: 10.1177/1479164118795252

[96] Evert AB, Boucher JL, Cypress M, et al. Nutrition Therapy Recommendations for the Management of Adults With Diabetes. Diabetes Care. 2014; 37 (Supplement_1): S120 - S143. doi: 10.2337/dc14-S120

[97] Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12): 2669 - 2701. doi: 10.2337/dci18-0033

[98] MacLeod J, Franz MJ, Handu D, et al. Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Nutrition Intervention Evidence Reviews and Recommendations. J Acad Nutr Diet. 2017; 117(10): 1637 - 1658. doi: 10.1016/j.jand.2017.03.023

[99] Mudaliar U, Zabetian A, Goodman M, et al. Cardiometabolic Risk Factor Changes Observed in Diabetes Prevention Programs in US Settings: A Systematic Review and Meta-analysis. PLOS Med. 2016; 13(7): e1002095. doi: 10.1371/journal.pmed.1002095

[100] Balk EM, Earley A, Raman G, et al. Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force. Ann Intern Med. 2015; 163(6): 437 - 451. doi: 10.7326/M15-0452

[101] Franz MJ, Boucher JL, Rutten-Ramos S, et al. Lifestyle Weight-Loss Intervention Outcomes in Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Acad Nutr Diet. 2015; 115(9): 1447 - 1463. doi: 10.1016/j.jand.2015.02.031

[102] Schwingshackl L, Chaimani A, Hoffmann G, et al. A network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus. Eur J Epidemiol. 2018; 33(2): 157 - 170. doi: 10.1007/s10654-017-0352-x

[103] Trumbo P, Schlicker S, Yates AA, et al. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 2002; 102(11): 1621 - 1630.

[104] Hamdy O, Mottalib A, Morsi A, et al. Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study. BMJ Open Diabetes Res Care. 2017; 5(1): e000259. doi: 10.1136/bmjdrc-2016-000259

[105] Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018; 391(10120): 541 - 551. doi: 10.1016/S0140-6736(17)33102-1

[106] Mottalib A, Salsberg V, Mohd-Yusof B-N, et al. Effects of nutrition therapy on HbA1c and cardiovascular disease risk factors in overweight and obese patients with type 2 diabetes. Nutr J. 2018; 17(1): 42. doi: 10.1186/s12937-018-0351-0

[107] Estruch R, Ros E, J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018; 378(25): e34. doi: 10.1056/NEJMoa1800389

[108] Saslow LR, Daubenmier JJ, Moskowitz JT, et al. Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or prediabetes. Nutr Diabetes. 2017; 7(12): 304. doi: 10.1038/s41387-017-0006-9

[109] Emadian A, Andrews RC, England CY, et al. The effect of macronutrients on glycaemic control: a systematic review of dietary randomised controlled trials in overweight and obese adults with type 2 diabetes in which there was no difference in weight loss between treatment groups. Br J Nutr. 2015; 114(10): 1656 - 1666. doi: 10.1017/S0007114515003475

[110] Gardner CD, Trepanowski JF, Del Gobbo LC, et al. Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion. JAMA. 2018; 319(7): 667 - 679. doi: 10.1001/jama.2018.0245

[111] Schwingshackl L, Schwedhelm C, Hoffmann G, et al. Food groups and risk of all-cause mortality: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2017; 105(6): 1462 - 1473. doi: 10.3945/ajcn.117.153148

[112] Grotz VL, Pi-Sunyer X, Porte D, et al. A 12-week randomized clinical trial investigating the potential for sucralose to affect glucose homeostasis. Regul Toxicol Pharmacol. 2017; 8822 - 33. doi: 10.1016/j.yrtph.2017.05.011

[113] Miller PE, Perez V. Low-calorie sweeteners and body weight and composition: a meta-analysis of randomized controlled trials and prospective cohort studies. Am J Clin Nutr. 2014; 100(3): 765 - 777. doi: 10.3945/ajcn.113.082826

[114] Rogers PJ, Hogenkamp PS, de Graaf C, et al. Does low-energy sweetener consumption affect energy intake and body weight? A systematic review, including meta-analyses, of the evidence from human and animal studies. Int J Obes. 2016; 40(3): 381 - 394. doi: 10.1038/ijo.2015.177

[115] Franz MJ, MacLeod J, Evert A, et al. Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Systematic Review of Evidence for Medical Nutrition Therapy Effectiveness and Recommendations for Integration into the Nutrition Care Process. J Acad Nutr Diet. 2017; 117(10): 1659 - 1679. doi: 10.1016/j.jand.2017.03.022

[116] Bowen ME, Cavanaugh KL, Wolff K, et al. The diabetes nutrition education study randomized controlled trial: A comparative effectiveness study of approaches to nutrition in diabetes self-management education. Patient Educ Couns. 2016; 99(8): 1368 - 1376. doi: 10.1016/j.pec.2016.03.017

[117] Savoca MR, Miller CK, Ludwig DA. Food habits are related to glycemic control among people with type 2 diabetes mellitus. J Am Diet Assoc. 2004; 104(4): 560 - 566. doi: 10.1016/j.jada.2004.01.013

[118] Arnold L, Mann JI, Ball MJ. Metabolic effects of alterations in meal frequency in type 2 diabetes. Diabetes Care. 1997; 20(11): 1651 - 1654. doi: 10.2337/diacare.20.11.1651

[119] Marran KJ, Davey B, Lang A, et al. Exponential increase in postprandial blood-glucose exposure with increasing carbohydrate loads using a linear carbohydrate-to-insulin ratio. South African Med J. 2013; 103(7): 461 - 463. doi: 10.7196/samj.6382

[120] Rossi MCE, Nicolucci A, Di Bartolo P, et al. Diabetes Interactive Diary: A New Telemedicine System Enabling Flexible Diet and Insulin Therapy While Improving Quality of Life: An open-label, international, multicenter, randomized study. Diabetes Care. 2010; 33(1): 109 - 115. doi: 10.2337/dc09-1327

[121] Bergenstal RM, Johnson M, Powers MA, et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care. 2008; 31(7): 1305 - 1310. doi: 10.2337/dc07-2137

[122] Tunbridge FK, Home PD, Murphy M, et al. Does flexibility at mealtimes disturb blood glucose control on a multiple insulin injection regimen? Diabet Med. 1991; 8(9): 833 - 838. doi: 10.1111/j.1464-5491.1991.tb02121.x

[123] Huckvale K, Adomaviciute S, Prieto JT, et al. Smartphone apps for calculating insulin dose: a systematic assessment. BMC Med. 2015; 13(1): 106. doi: 10.1186/s12916-015-0314-7

[124] U.S. Department of Health and Human Services, U.S. Department of Agriculture. 2015 - 2020 Dietary Guidelines for Americans. 8th Edition. Washington, 2015

[125] Hegde S V., Adhikari P, M N, et al. Effect of daily supplementation of fruits on oxidative stress indices and glycaemic status in type 2 diabetes mellitus. Complement Ther Clin Pract. 2013; 19(2): 97 - 100. doi: 10.1016/j.ctcp.2012.12.002

[126] Shin JY, Kim JY, Kang HT, et al. Effect of fruits and vegetables on metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Int J Food Sci Nutr. 2015; 66(4): 416 - 425. doi: 10.3109/09637486.2015.1025716

[127] Petersen KS, Clifton PM, Blanch N, et al. Effect of improving dietary quality on carotid intima media thickness in subjects with type 1 and type 2 diabetes: a 12-mo randomized controlled trial. Am J Clin Nutr. 2015; 102(4): 771 - 779. doi: 10.3945/ajcn.115.112151

[128] Viguiliouk E, Kendall CWC, Blanco Mejia S, et al. Effect of tree nuts on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled dietary trials. PLoS One. 2014; 9(7): e103376. doi: 10.1371/journal.pone.0103376

[129] PLB, Ross AB, Kristensen M. Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. Am J Clin Nutr. 2015; 102(3): 556 - 572. doi: 10.3945/ajcn.115.109165

[130] Te Morenga LA, Howatson AJ, Jones RM, et al. Dietary sugars and cardiometabolic risk: systematic review and meta-analyses of randomized controlled trials of the effects on blood pressure and lipids. Am J Clin Nutr. 2014; 100(1): 65 - 79. doi: 10.3945/ajcn.113.081521

[131] Wang X, Ouyang Y, Liu J, et al. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ. 2014; 349g4490. doi: 10.1136/bmj.g4490

[132] Ekinci EI, Clarke S, Thomas MC, et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care. 2011; 34(3): 703 - 709. doi: 10.2337/dc10-1723

[133] Azadbakht L, Fard NRP, Karimi M, et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. Diabetes Care. 2011; 34(1): 55 - 57. doi: 10.2337/dc10-0676

[134] Chiavaroli L, de Souza RJ, Ha V, et al. Effect of Fructose on Established Lipid Targets: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. J Am Heart Assoc. 2015; 4(9): e001700. doi: 10.1161/JAHA.114.001700

[135] Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity. Circulation. 2016; 133(2): 187 - 225. doi: 10.1161/CIRCULATIONAHA.115.018585

[136] Blomster JI, Zoungas S, Chalmers J, et al. The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes. Diabetes Care. 2014; 37(5): 1353 - 1359. doi: 10.2337/dc13-2727

[137] Ahmed AT, Karter AJ, Warton EM, et al. The relationship between alcohol consumption and glycemic control among patients with diabetes: the Kaiser Permanente Northern California Diabetes Registry. J Gen Intern Med. 2008; 23(3): 275 - 282. doi: 10.1007/s11606-007-0502-z

[138] Pietraszek A, Gregersen S, Hermansen K. Alcohol and type 2 diabetes. A review. Nutr Metab Cardiovasc Dis. 2010; 20(5): 366 - 375. doi: 10.1016/j.numecd.2010.05.001

[139] 2018 Physical Activity Guidelines Advisory Committee. 2018 Physical Activity Guidelines Advisory Committee Scientific Report. Washington, 2018

[140] NG, Haddad E, Kenny GP, et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001; 286(10): 1218 - 1227. doi: 10.1001/jama.286.10.1218

[141] Rejeski WJ, Ip EH, Bertoni AG, et al. Lifestyle Change and Mobility in Obese Adults with Type 2 Diabetes. N Engl J Med. 2012; 366(13): 1209 - 1217. doi: 10.1056/NEJMoa1110294

[142] Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and Type 2 Diabetes: The American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. Diabetes Care. 2010; 33(12): 2692 - 2696. doi: 10.2337/dc10-1548

[143] Church TS, Blair SN, Cocreham S, et al. Effects of Aerobic and Resistance Training on Hemoglobin A 1c Levels in Patients With Type 2 Diabetes. JAMA. 2010; 304(20): 2253 - 2262. doi: 10.1001/jama.2010.1710

[144] Sluik D, Buijsse B, Muckelbauer R, et al. Physical Activity and Mortality in Individuals With Diabetes Mellitus. Arch Intern Med. 2012; 172(17): 1285 - 1295. doi: 10.1001/archinternmed.2012.3130

[145] Colberg SR, Sigal RJ, Yardley JE, et al. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care. 2016; 39(11): 2065 - 2079. doi: 10.2337/dc16-1728

[146] Jelleyman C, Yates T, O'Donovan G, et al. The effects of high-intensity interval training on glucose regulation and insulin resistance: a meta-analysis. Obes Rev. 2015; 16(11): 942 - 961. doi: 10.1111/obr.12317

[147] Little JP, Gillen JB, Percival ME, et al. Low-volume high-intensity interval training reduces hyperglycemia and increases muscle mitochondrial capacity in patients with type 2 diabetes. J Appl Physiol. 2011; 111(6): 1554 - 1560. doi: 10.1152/japplphysiol.00921.2011

[148] U.S. Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans. 2008

[149] Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019pii: S0140 - 6736(19) 31149-3 [Epub ahead of print]. doi: 10.1016/S0140-6736(19)31149-3

[150] Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019; 380(4): 347 - 357. doi: 10.1056/NEJMoa1812389

[151] Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117 - 2128. doi: 10.1056/NEJMoa1504720

[152] Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7): 644 - 657. doi: 10.1056/NEJMoa1611925

[153] Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020; 383(15): 1425 - 1435. doi: 10.1056/NEJMoa2004967

[154] Maruthur NM, Tseng E, Hutfless S, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. Ann Intern Med. 2016; 164(11): 740 - 751. doi: 10.7326/M15-2650

[155] Matthews DR, PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019; 394(10208): 1519 - 1529. doi: 10.1016/S0140-6736(19)32131-2

[156] Phung OJ, Sobieraj DM, Engel SS, et al. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes, Obes Metab. 2014; 16(5): 410 - 417. doi: 10.1111/dom.12233

[157] Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT. Diabetes, Obes Metab. 2015; 17(3): 268 - 275. doi: 10.1111/dom.12417

[158] Henry RR, Murray A V., Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012; 66(5): 446 - 456. doi: 10.1111/j.1742-1241.2012.02911.x

[159] Hadjadj S, Rosenstock J, Meinicke T, et al. Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes. Diabetes Care. 2016; 39(10): 1718 - 1728. doi: 10.2337/dc16-0522

[160] Rosenstock J, Chuck L, M, et al. Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Type 2 Diabetes. Diabetes Care. 2016; 39(3): 353 - 362. doi: 10.2337/dc15-1736

[161] Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4): 311 - 322. doi: 10.1056/NEJMoa1603827

[162] Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19): 1834 - 1844. doi: 10.1056/NEJMoa1607141

[163] Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393(10166): 31 - 39. doi: 10.1016/S0140-6736(18)32590-X

[164] Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018; 6(2): 105 - 113. doi: 10.1016/S2213-8587(17)30412-6

[165] Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009; 160(6): 909 - 917. doi: 10.1530/EJE-09-0101

[166] Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019; 139(17): 2022 - 2031. doi: 10.1161/CIRCULATIONAHA.118.038868

[167] Singh AK, Singh R. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. Expert Rev Clin Pharmacol. 2019; 12(4): 299 - 308. doi: 10.1080/17512433.2019.1588110

[168] Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 2018; 137(2): 119 - 129. doi: 10.1161/CIRCULATIONAHA.117.028268

[169] Mann JFE, DD, Brown-Frandsen K, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(9): 839 - 848. doi: 10.1056/NEJMoa1616011

[170] Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019; 394(10193): 131 - 138. doi: 10.1016/S0140-6736(19)31150-X

[171] Singh S, Wright EE, Kwan AYM, et al. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes, Obes Metab. 2017; 19(2): 228 - 238. doi: 10.1111/dom.12805

[172] Levin PA, Nguyen H, Wittbrodt E, et al. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, Metab Syndr Obes Targets Ther. 2017; 10123 - 139. doi: 10.2147/DMSO.S130834

[173] Abd El Aziz MS, Kahle M, Meier JJ, et al. A meta-analysis comparing clinical effects of short-or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes, Obes Metab. 2017; 19(2): 216 - 227. doi: 10.1111/dom.12804

[174] Giorgino F, Benroubi M, Sun J-H, et al. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes Care. 2015; 38(12): 2241 - 2249. doi: 10.2337/dc14-1625

[175] Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, mul. Lancet Diabetes Endocrinol. 2017; 5(5): 355 - 366. doi: 10.1016/S2213-8587(17) 30085-2

[176] Davies M, Heller S, Sreenan S, et al. Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care. 2013; 36(5): 1368 - 1376. doi: 10.2337/dc12-1333

[177] Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010; 375(9733): 2234 - 2243. doi: 10.1016/S0140-6736(10) 60406-0

[178] Дедов И.И., Шестакова М.В., Петеркова В.А., и др. Проект рекомендаций Российской ассоциации эндокринологов по применению биосимиляров инсулина. Сахарный диабет. 2021; 24(1): 76 - 79.

[179] Erpeldinger S, Rehman MB, Berkhout C, et al. Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. BMC Endocr Disord. 2016; 16(1): 39. doi: 10.1186/s12902-016-0120-z

[180] Owens DR, Traylor L, Mullins P, et al. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Res Clin Pract. 2017; 12457 - 65. doi: 10.1016/j.diabres.2016.10.022

[181] Дедов И.И., Шестакова М.В., Аметов А.С., и др. Инициация и интенсификация сахароснижающей терапии у больных сахарным диабетом 2 типа: обновление консенсуса совета экспертов Российской ассоциации эндокринологов (2015). Сахарный диабет. 2015; 18(1): 5 - 23. doi: 10.14341/DM201515-23

[182] Raskin P, Allen E, Hollander P, et al. Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care. 2005; 28(2): 260 - 265. doi: 10.2337/diacare.28.2.260

[183] Porcellati F, Lucidi P, Cioli P, et al. Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes. Diabetes Care. 2015; 38(3): 503 - 512. doi: 10.2337/dc14-0649

[184] Wang Z, Hedrington MS, Gogitidze Joy N, et al. Dose-Response Effects of Insulin Glargine in Type 2 Diabetes. Diabetes Care. 2010; 33(7): 1555 - 1560. doi: 10.2337/dc09-2011

[185] Cai X, Gao X, Yang W, et al. Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis. Expert Opin Pharmacother. 2017; 18(17): 1789 - 1798. doi: 10.1080/14656566.2017.1400011

[186] Gough SCL, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 di. Lancet Diabetes Endocrinol. 2014; 2(11): 885 - 893. doi: 10.1016/S2213-8587(14)70174-3

[187] Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care. 2016; 39(11): 2026 - 2035. doi: 10.2337/dc16-0917

[188] American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45 (Supplement_1): S125 - S143. doi: 10.2337/dc22-S009

[189] Rosenstock J, Emral R, Sauque-Reyna L, et al. Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial. Diabetes Care. 2021dc210393. doi: 10.2337/dc21-0393

[190] Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. Can Med Assoc J. 2009; 180(4): 385 - 397. doi: 10.1503/cmaj.081041

[191] Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane database Syst Rev. 2007(2): CD005613. doi: 10.1002/14651858.CD005613.pub3

[192] Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. Diabetes Res Clin Pract. 2008; 81(2): 184 - 189. doi: 10.1016/j.diabres.2008.04.007

[193] Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26(11): 3080 - 3086. doi: 10.2337/diacare.26.11.3080

[194] Hermansen K, Davies M, Derezinski T, et al. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care. 2006; 29(6): 1269 - 1274. doi: 10.2337/dc05-1365

[195] Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-na ve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes, Obes Metab. 2015; 17(4): 386 - 394. doi: 10.1111/dom.12438

[196] Terauchi Y, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes, Obes Metab. 2016; 18(4): 366 - 374. doi: 10.1111/dom.12618

[197] H, Bergenstal RM, Bolli GB, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extensi. Diabetes, Obes Metab. 2015; 17(12): 1142 - 1149. doi: 10.1111/dom.12532

[198] Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017; 377(8): 723 - 732. doi: 10.1056/NEJMoa1615692

[199] Rodbard HW, Cariou B, Zinman B, et al. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013; 30(11): 1298 - 1304. doi: 10.1111/dme.12303

[200] Wysham C, Bhargava A, Chaykin L, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes. JAMA. 2017; 318(1): 45 - 56. doi: 10.1001/jama.2017.7117

[201] Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012; 35(12): 2464 - 2471. doi: 10.2337/dc12-1205

[202] Madenidou A-V, Paschos P, Karagiannis T, et al. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes. Ann Intern Med. 2018; 169(3): 165 - 174. doi: 10.7326/M18-0443

[203] Roussel R, Ritzel R, Corfec E, et al. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300 U/mL vs glargine 100 U/mL in T2DM. Diabetes Metab. 2018; 44(5): 402 - 409. doi: 10.1016/j.diabet.2018.02.002

[204] Davidson JA, Liebl A, Christiansen JS, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: A meta-analysis. Clin Ther. 2009; 31(8): 1641 - 1651. doi: 10.1016/j.clinthera.2009.08.011

[205] Rys P, Wojciechowski P, Siejka S, et al. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus - a systematic review and meta-analysis. Int J Clin Pract. 2014; 68(3): 304 - 313. doi: 10.1111/ijcp.12337

[206] Riddle MC, H, Bolli GB, et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes, Obes Metab. 2015; 17(9): 835 - 842. doi: 10.1111/dom.12472

[207] Heller S, Bode B, Kozlovski P, et al. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus. J Diabetes. 2013; 5(4): 482 - 491. doi: 10.1111/1753-0407.12060

[208] Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes, Obes Metab. 2009; 11(1): 53 - 59. doi: 10.1111/j.1463-1326.2008.00934.x

[209] Rodbard HW, Visco VE, Andersen H, et al. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 2014; 2(1): 30 - 37. doi: 10.1016/S2213-8587(13)70090-1

[210] Diamant M, Nauck MA, Shaginian R, et al. Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes. Diabetes Care. 2014; 37(10): 2763 - 2773. doi: 10.2337/dc14-0876

[211] Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014; 384(9961): 2228 - 2234. doi: 10.1016/S0140-6736(14)61335-0

[212] Maiorino MI, Chiodini P, Bellastella G, et al. Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2017; 40(4): 614 - 624. doi: 10.2337/dc16-1957

[213] Buse JB, T, Thurman J, et al. Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). Diabetes Care. 2014; 37(11): 2926 - 2933. doi: 10.2337/dc14-0785

[214] Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care. 2016; 39(11): 1972 - 1980. doi: 10.2337/dc16-1495

[215] Triplitt C. How to Initiate, Titrate, and Intensify Insulin Treatment in Type 2 Diabetes. US Pharm. 2017; 32(10): 10 - 16.

[216] Elliott J, Lawton J, Rankin D, et al. The 5x1 DAFNE study protocol: a cluster randomised trial comparing a standard 5 day DAFNE course delivered over 1 week against DAFNE training delivered over 1 day a week for 5 consecutive weeks. BMC Endocr Disord. 2012; 12(1): 28. doi: 10.1186/1472-6823-12-28

[217] Haas L, Maryniuk M, Beck J, et al. National Standards for Diabetes Self-Management Education and Support. Diabetes Care. 2013; 36 (Supplement_1): S100 - S108. doi: 10.2337/dc13-S100

[218] Powers MA, Bardsley J, Cypress M, et al. Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care. 2015; 38(7): 1372 - 1382. doi: 10.2337/dc15-0730

[219] Майоров А.Ю., Мельникова О.Г., Котешкова О.М., и др. Техника инъекций и инфузии при лечении сахарного диабета. Методическое руководство. Москва: ООО 'АРТИНФО', 2018

[220] Frid AH, Kreugel G, Grassi G, et al. New Insulin Delivery Recommendations. Mayo Clin Proc. 2016; 91(9): 1231 - 1255. doi: 10.1016/j.mayocp.2016.06.010

[221] Uzun S, Inanc N, Azal S. Determining optimal needle length for subcutaneous insulin injection. J Diab Nurs. 2001; 5(10): 83 - 87.

[222] Hirsch LJ, Gibney MA, Albanese J, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010; 26(6): 1531 - 1541. doi: 10.1185/03007995.2010.482499

[223] Miwa T, Itoh R, Kobayashi T, et al. Comparison of the Effects of a New 32-Gauge x 4-mm Pen Needle and a 32-Gauge x 6-mm Pen Needle on Glycemic Control, Safety, and Patient Ratings in Japanese Adults with Diabetes. Diabetes Technol Ther. 2012; 14(12): 1084 - 1090. doi: 10.1089/dia.2012.0170

[224] Nagai Y, Ohshige T, Arai K, et al. Comparison Between Shorter Straight and Thinner Microtapered Insulin Injection Needles. Diabetes Technol Ther. 2013; 15(7): 550 - 555. doi: 10.1089/dia.2012.0334

[225] Bergenstal RM, Strock ES, Peremislov D, et al. Safety and Efficacy of Insulin Therapy Delivered via a 4mm Pen Needle in Obese Patients With Diabetes. Mayo Clin Proc. 2015; 90(3): 329 - 338. doi: 10.1016/j.mayocp.2014.12.014

[226] Kreugel G, Kees J, Jongbloed A, et al. The influence of needle length on glycemic control and patient preference in obese diabetic patients. Diabetes. 2009; 58A117.

[227] Schwartz S, Hassman D, Shelmet J, et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther. 2004; 26(10): 1663 - 1678. doi: 10.1016/j.clinthera.2004.10.007

[228] Strauss K, Hannet I, McGonigle J, et al. Ultra-short (5 mm) insulin needles: Trial results and clinical recommendations. Pract Diabetes Int. 1999; 16(7): 218 - 222. doi: 10.1002/pdi.1960160711

[229] Kreugel G, Keers JC, Kerstens MN, et al. Randomized Trial on the Influence of the Length of Two Insulin Pen Needles on Glycemic Control and Patient Preference in Obese Patients with Diabetes. Diabetes Technol Ther. 2011; 13(7): 737 - 741. doi: 10.1089/dia.2011.0010

[230] McKay M, Compion G, Lytzen L. A Comparison of Insulin Injection Needles on Patients' Perceptions of Pain, Handling, and Acceptability: A Randomized, Open-Label, Crossover Study in Subjects with Diabetes. Diabetes Technol Ther. 2009; 11(3): 195 - 201. doi: 10.1089/dia.2008.0054

[231] Birkebaek NH, Solvig J, Hansen B, et al. A 4-mm Needle Reduces the Risk of Intramuscular Injections Without Increasing Backflow to Skin Surface in Lean Diabetic Children and Adults. Diabetes Care. 2008; 31(9): e65. doi: 10.2337/dc08-0977

[232] Schuler G, Pelz K, Kerp L. Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications? Diabetes Res Clin Pract. 1992; 16(3): 209 - 212.

[233] Johansson U-B, Amsberg S, Hannerz L, et al. Impaired Absorption of Insulin Aspart From Lipohypertrophic Injection Sites. Diabetes Care. 2005; 28(8): 2025 - 2027. doi: 10.2337/diacare.28.8.2025

[234] Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. BMJ. 2003; 327(7411): 383 - 384. doi: 10.1136/bmj.327.7411.383

[235] Chantelau E, Lee DM, Hemmann DM, et al. What makes insulin injections painful? BMJ. 1991; 303(6793): 26 - 27. doi: 10.1136/bmj.303.6793.26

[236] Caffrey R. Are All Syringes Created Equal?: How to choose and use today's insulin syringes. Am J Nurs. 2003; 103(6): 46 - 49.

[237] Braak EWT, Woodworth JR, Bianchi R, et al. Injection Site Effects on the Pharmacokinetics and Glucodynamics of Insulin Lispro and Regular Insulin. Diabetes Care. 1996; 19(12): 1437 - 1440. doi: 10.2337/diacare.19.12.1437

[238] Frid A. Fat thickness and insulin administration, what do we know? Infusystems Int. 2006; 5(3): 17 - 19.

[239] Lippert WC, Wall EJ. Optimal Intramuscular Needle-Penetration Depth. Pediatrics. 2008; 122(3): e556 - e563. doi: 10.1542/peds.2008-0374

[240] Sonoki K, Yoshinari M, Iwase M, et al. Regurgitation of Blood into Insulin Cartridges in the Pen-like Injectors. Diabetes Care. 2001; 24(3): 603 - 604. doi: 10.2337/diacare.24.3.603

[241] Shikata T, Karasawa T, Abe K, et al. Hepatitis B e Antigen and Infectivity of Hepatitis B Virus. J Infect Dis. 1977; 136(4): 571 - 576. doi: 10.1093/infdis/136.4.571

[242] Scioli D, Pizzella T, Vollaro L, et al. The action of VIRKON No Foam on the hepatitis B virus. Eur J Epidemiol. 1997; 13(8): 879 - 883. doi: 10.1023/A:1007399926095

[243] Herdman ML, Larck C, Schliesser SH, et al. Biological contamination of insulin pens in a hospital setting. Am J Heal Pharm. 2013; 70(14): 1244 - 1248. doi: 10.2146/ajhp120728

[244] Cochran J, Conn VS. Meta-analysis of Quality of Life Outcomes Following Diabetes Self-management Training. Diabetes Educ. 2008; 34(5): 81 - 823. doi: 10.1177/0145721708323640

[245] Foster G, Taylor SJC, Eldridge SE, et al. Self-management education programmes by lay leaders for people with chronic conditions. Cochrane database Syst Rev. 2007(4): CD005108. doi: 10.1002/14651858.CD005108.pub2

[246] Johnson TM, Murray MR, Huang Y. Associations Between Self-Management Education and Comprehensive Diabetes Clinical Care. Diabetes Spectr. 2010; 23(1): 41 - 46. doi: 10.2337/diaspect.23.1.41

[247] Rubino F, Nathan DM, Eckel RH, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016; 39(6): 861 - 877. doi: 10.2337/dc16-0236

[248] Cummings DE, Rubino F. Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia. 2018; 61(2): 257 - 264. doi: 10.1007/s00125-017-4513-y

[249] Дедов И.И., Мельниченко Г.А., Шестакова М.В., и др. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 3-ий пересмотр (лечение морбидного ожирения у взрослых). Ожирение и метаболизм. 2018; 15(1): 53 - 70. doi: 10.14341/OMET2018153-70

[250] Buchwald H, Estok R, Fahrbach K, et al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. Am J Med. 2009; 122(3): 248 - 256.e5. doi: 10.1016/j.amjmed.2008.09.041

[251] Rubino F, Kaplan LM, Schauer PR, et al. The Diabetes Surgery Summit Consensus Conference. Ann Surg. 2010; 251(3): 399 - 405. doi: 10.1097/SLA.0b013e3181be34e7

[252] Zimmet P, Alberti KGM, Rubino F, et al. IDF's view of bariatric surgery in type 2 diabetes. Lancet. 2011; 378(9786): 108 - 110. doi: 10.1016/S0140-6736(11)61027-1

[253] Kasama K, Mui W, Lee WJ, et al. IFSO-APC Consensus Statements 2011. Obes Surg. 2012; 22(5): 677 - 684. doi: 10.1007/s11695-012-0610-7

[254] Wentworth JM, Burton P, Laurie C, et al. Five-Year Outcomes of a Randomized Trial of Gastric Band Surgery in Overweight but Not Obese People With Type 2 Diabetes. Diabetes Care. 2017; 40(4): e44 - e45. doi: 10.2337/dc16-2149

[255] Cummings DE, Arterburn DE, Westbrook EO, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia. 2016; 59(5): 945 - 953. doi: 10.1007/s00125-016-3903-x

[256] Busetto L, Dicker D, Azran C, et al. Practical Recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management. Obes Facts. 2017; 10(6): 597 - 632. doi: 10.1159/000481825

[257] O'Kane M, Parretti HM, Pinkney J, et al. British Obesity and Metabolic Surgery Society Guidelines on perioperative and postoperative biochemical monitoring and micronutrient replacement for patients undergoing bariatric surgery-2020 update. Obes Rev. 2020; 21(11): e13087. doi: 10.1111/obr.13087

[258] Всемирная Организация Здравоохранения. Терапевтическое обучение больных. Программы непрерывного обучения для работников здравоохранения в области профилактики хронических заболеваний. Отчет рабочей группы ВОЗ. Москва, 1998

[259] Beck J, Greenwood DA, Blanton L, et al. 2017 National Standards for Diabetes Self-Management Education and Support. Diabetes Care. 2017; 40(10): 1409 - 1419. doi: 10.2337/dci17-0025

[260] Muhlhauser I, Berger M. Patient education - evaluation of a complex intervention. Diabetologia. 2002; 45(12): 1723 - 1733. doi: 10.1007/s00125-002-0987-2

[261] Майоров А.Ю., Суркова Е.В., Мотовилин О.Г., и др. Обучение больных диабетом: синтез доказательной медицины и психологического подхода. Сахарный диабет. 2011; 14(1): 46 - 52. doi: 10.14341/2072-0351-6249

[262] Deakin T, Whitham C. Structured patient education: the X-PERT Programme. Br J Community Nurs. 2009; 14(9): 398 - 404. doi: 10.12968/bjcn.2009.14.9.43916

[263] Clark M. Diabetes self-management education: A review of published studies. Prim Care Diabetes. 2008; 2(3): 113 - 120. doi: 10.1016/j.pcd.2008.04.004

[264] Steinsbekk A, Rygg L, Lisulo M, et al. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis. BMC Health Serv Res. 2012; 12(1): 213. doi: 10.1186/1472-6963-12-213

[265] Deakin T, McShane CE, Cade JE, et al. Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane database Syst Rev. 2005(2): CD003417. doi: 10.1002/14651858.CD003417.pub2

[266] Norris SL, Lau J, Smith SJ, et al. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002; 25(7): 1159 - 1171. doi: 10.2337/diacare.25.7.1159

[267] He X, Li J, Wang B, et al. Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis. Endocrine. 2017; 55(3): 712 - 731. doi: 10.1007/s12020-016-1168-2

[268] Assal JP. Educating the diabetic patient: which programme is specific to IDDM and to NIDDM? In: de Gryter W (ed) Concepts for the ideal diabetes clinic. New York, 1992, pp. 89 - 104

[269] Анциферов М.Б., Майоров А.Ю., Суркова Е.В., и др. Пособие для врачей "Структурированные программы обучения больных сахарным диабетом". 2003

[270] Майоров А.Ю., Суркова Е.В., Галстян Г.Р., et al. Структурированная программа обучения больных сахарным диабетом 2 типа на инсулинотерапии (с набором плакатов и карточек продуктов). 2006

[271] Мельниченко Г.А., Суркова Е.В., Майоров А.Ю., и др. Результаты применения структурированной программы обучения больных сахарным диабетом 2 типа на инсулинотерапии. Сахарный диабет. 2008; 11(4): 71 - 75. doi: 10.14341/2072-0351-5595

[272] Duncan I, Ahmed T, Li Q (Emily), et al. Assessing the Value of the Diabetes Educator. Diabetes Educ. 2011; 37(5): 638 - 657. doi: 10.1177/0145721711416256

[273] DESG Working Group. Basic Curriculum for Health Care Professionals on Diabetes Therapeutic Education. 2001

[274] Дедов И.И., Суркова Е.В., Майоров А.Ю., и др. Программа подготовки специалистов в области обучения больных сахарным диабетом. Сахарный диабет. 2003; 6(1): 44 - 47. doi: 10.14341/2072-0351-6045

[275] Дедов И.И., Суркова Е.В., Майоров А.Ю., и др. Терапевтическое обучение больных сахарным диабетом. Москва: Реафарм, 2004

[276] Суркова Е.В., Майоров А.Ю., Галстян Г.Р., и др. Обучение больных сахарным диабетом: Руководство для эндокринологов. Москва: Медицина для Вас, 2007

[277] Sadosky A, Schaefer C, Mann R, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes. 2013; 679 - 92. doi: 10.2147/DMSO.S37415

[278] Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2): 162 - 173. doi: 10.1016/S1474-4422(14)70251-0

[279] Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: High-dose monotherapy or their combination? The "COMBO-DN study" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013; 154(12): 2616 - 2625. doi: 10.1016/j.pain.2013.05.043

[280] Waldfogel JM, Nesbit SA, Dy SM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life. Neurology. 2017; 88(20): 1958 - 1967. doi: 10.1212/WNL.0000000000003882

[281] Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017; 6CD007938. doi: 10.1002/14651858.CD007938.pub4

[282] Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006; 67(8): 1411 - 1420. doi: 10.1212/01.wnl.0000240225.04000.1a

[283] Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011; 27(1): 151 - 162. doi: 10.1185/03007995.2010.537589

[284] Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care. 2013; 36(5): 1384 - 1395. doi: 10.2337/dc12-2480

[285] Cryer PE. Diverse Causes of Hypoglycemia-Associated Autonomic Failure in Diabetes. N Engl J Med. 2004; 350(22): 2272 - 2279. doi: 10.1056/NEJMra031354

[286] Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. J Clin Endocrinol Metab. 2013; 98(5): 1845 - 1859. doi: 10.1210/jc.2012-4127

[287] Slama G, Traynard PY, Desplanque N, et al. The search for an optimized treatment of hypoglycemia. Carbohydrates in tablets, solutin, or gel for the correction of insulin reactions. Arch Intern Med. 1990; 150(3): 589 - 593.

[288] Cryer PE, Preceded by: Cryer PE. Hypoglycemia in diabetes: pathophysiology, prevalence, and prevention. American Diabetes Association, https://www.worldcat.org/title/hypoglycemia-in-diabetes-pathophysiology-prevalence-and-prevention/oclc/953848679 (2016, accessed 28 July 2019)

[289] Karter AJ, Moffet HH, Liu JY, et al. Surveillance of Hypoglycemia - Limitations of Emergency Department and Hospital Utilization Data. JAMA Intern Med. 2018; 178(7): 987 - 988. doi: 10.1001/jamainternmed.2018.1014

[290] Eli Lilly Canada Inc. Glucagon (rDNA Origin) Product Monograph. Toronto, 2012

[291] Nordisk N. (glucagon) Product monograph. Bagsvaerd, 2002

[292] Стандарт санаторно-курортной помощи больным сахарным диабетом. Проблемы стандартизации в здравоохранении. 2005(1): 106 - 107.

[293] Агасиев А.Р. Потребность больных сахарным диабетом в дополнительных лечебно-диагностических услугах при санаторно-курортном лечении. Современная медицина: актуальные вопросы. 2015 (42 - 43): 93 - 97.

[294] Приказ Минздрава РФ от 28.09.2020 N 1029Н "Об утверждении перечней медицинских показаний и противопоказаний для санаторно-курортного лечения"

[295] Мустафина С.В., Рымар О.Д., Сазонова О.В., и др. Валидизация финской шкалы риска "FINDRISC" на европеоидной популяции Сибири. Сахарный диабет. 2016; 19(2): 113 - 118. doi: 10.14341/DM200418-10

[296] J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003; 26(3): 725 - 731. doi: 10.2337/diacare.26.3.725

[297] Tuomilehto J, J, Eriksson JG, et al. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. N Engl J Med. 2001; 344(18): 1343 - 1350. doi: 10.1056/NEJM200105033441801

[298] Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6): 393 - 403. doi: 10.1056/NEJMoa012512

[299] Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (London, England). 2009; 374(9702): 1677 - 1686. doi: 10.1016/S0140-6736(09)61457-4

[300] Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. lancet Diabetes Endocrinol. 2015; 3(11): 866 - 875. doi: 10.1016/S2213-8587(15)00291-0

[301] Inker LA, Grams ME, Levey AS, et al. Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. Am J Kidney Dis. 2019; 73(2): 206 - 217. doi: 10.1053/j.ajkd.2018.08.013

[302] American Diabetes Association. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45 (Supplement_1): S175 - S184. doi: 10.2337/dc22-S011

[303] James MT, Grams ME, Woodward M, et al. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. Am J Kidney Dis. 2015; 66(4): 602 - 612. doi: 10.1053/j.ajkd.2015.02.338

[304] Eberle C, Stichling S. Clinical Improvements by Telemedicine Interventions Managing Type 1 and Type 2 Diabetes: Systematic Meta-review. J Med Internet Res. 2021; 23(2): e23244. doi: 10.2196/23244

[305] Hu Y, Wen X, Wang F, et al. Effect of telemedicine intervention on hypoglycaemia in diabetes patients: A systematic review and meta-analysis of randomised controlled trials. J Telemed Telecare. 2019; 25(7): 402 - 413. doi: 10.1177/1357633X18776823

[306] Wu C, Wu Z, Yang L, et al. Evaluation of the clinical outcomes of telehealth for managing diabetes. Medicine (Baltimore). 2018; 97(43): e12962. doi: 10.1097/MD.0000000000012962

[307] de Boer IH, Caramori ML, Chan JCN, et al. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020; 98(4): S1 - S115. doi: 10.1016/j.kint.2020.06.019

[308] Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014; 37(10): 2864 - 2883. doi: 10.2337/dc14-1296

[309] Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (London, England). 2012; 380(9854): 1662 - 1673. doi: 10.1016/S0140-6736(12)61350-6

[310] Kramer HJ, Nguyen QD, Curhan G, et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003; 289(24): 3273 - 3277. doi: 10.1001/jama.289.24.3273

[311] Kasiske BL, Lakatua JD, Ma JZ, et al. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998; 31(6): 954 - 961.

[312] Murray DP, Young L, Waller J, et al. Is Dietary Protein Intake Predictive of 1-Year Mortality in Dialysis Patients? Am J Med Sci. 2018; 356(3): 234 - 243. doi: 10.1016/j.amjms.2018.06.010

[313] He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane database Syst Rev. 2004(3): CD004937. doi: 10.1002/14651858.CD004937

[314] Mills KT, Chen J, Yang W, et al. Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. JAMA. 2016; 315(20): 2200 - 2210. doi: 10.1001/jama.2016.4447

[315] Nilsson E, Gasparini A, J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol. 2017; 245277 - 284. doi: 10.1016/j.ijcard.2017.07.035

[316] Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. lancet Diabetes Endocrinol. 2014; 2(10): 801 - 809. doi: 10.1016/S2213-8587(14)70156-1

[317] Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. lancet Diabetes Endocrinol. 2017; 5(6): 431 - 437. doi: 10.1016/S2213-8587(17)30104-3

[318] Zoungas S, Chalmers J, Neal B, et al. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N Engl J Med. 2014; 371(15): 1392 - 1406. doi: 10.1056/NEJMoa1407963

[319] Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019; 7(11): 845 - 854. doi: 10.1016/S2213-8587(19)30256-6

[320] Lo KB, Gul F, Ram P, et al. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis. Cardiorenal Med. 2020; 10(1): 1 - 10. doi: 10.1159/000503919

[321] Salah HM, Al'Aref SJ, Khan MS, et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes - Systematic review and meta-analysis of randomized placebo-controlled trials. Am Heart J. 2021; 23210 - 22. doi: 10.1016/j.ahj.2020.10.064

[322] McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. JAMA Cardiol. 2021; 6(2): 148. doi: 10.1001/jamacardio.2020.4511

[323] Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4): 323 - 334. doi: 10.1056/NEJMoa1515920

[324] Cherney DZI, Charbonnel B, Cosentino F, et al. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021; 64(6): 1256 - 1267. doi: 10.1007/s00125-021-05407-5

[325] Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019; 380(24): 2295 - 2306. doi: 10.1056/NEJMoa1811744

[326] Heerspink HJL, B V., Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15): 1436 - 1446. doi: 10.1056/NEJMoa2024816

[327] Lo C, Toyama T, Wang Y, et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane database Syst Rev. 2018; 9CD011798. doi: 10.1002/14651858.CD011798.pub2

[328] Kristensen SL, R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019; 7(10): 776 - 785. doi: 10.1016/S2213-8587(19)30249-9

[329] Leehey DJ, Zhang JH, Emanuele N V., et al. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial. Clin J Am Soc Nephrol. 2015; 10(12): 2159 - 2169. doi: 10.2215/CJN.02850315

[330] Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015; 313(6): 603 - 615. doi: 10.1001/jama.2014.18574

[331] Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12): 861 - 869. doi: 10.1056/NEJMoa011161

[332] Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993; 118(8): 577 - 581. doi: 10.7326/0003-4819-118-8-199304150-00001

[333] Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3): 145 - 153. doi: 10.1056/NEJM200001203420301

[334] Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017; 6(7): pii: e005428. doi: 10.1161/JAHA.116.005428

[335] Sumida K, Molnar MZ, Potukuchi PK, et al. Changes in Albuminuria and Subsequent Risk of Incident Kidney Disease. Clin J Am Soc Nephrol. 2017; 12(12): 1941 - 1949. doi: 10.2215/CJN.02720317

[336] Weil EJ, Fufaa G, Jones LI, et al. Effect of Losartan on Prevention and Progression of Early Diabetic Nephropathy in American Indians With Type 2 Diabetes. Diabetes. 2013; 62(9): 3224 - 3231. doi: 10.2337/db12-1512

[337] Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013; 369(20): 1892 - 1903. doi: 10.1056/NEJMoa1303154

[338] Bakris GL, Agarwal R, Chan JC, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015; 314(9): 884 - 894. doi: 10.1001/jama.2015.10081

[339] Filippatos G, Anker SD, M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016; 37(27): 2105 - 2114. doi: 10.1093/eurheartj/ehw132

[340] Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020; 383(23): 2219 - 2229. doi: 10.1056/NEJMoa2025845

[341] Smart NA, Dieberg G, Ladhani M, et al. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane database Syst Rev. 2014(6): CD007333. doi: 10.1002/14651858.CD007333.pub2

[342] Аветисов С.Э., Егоров Е.А., Мошетова Л.К., и др. Офтальмология. Национальное руководство. Краткое издание. Москва: ГЭОТАР-Медиа, 2014

[343] Giusti C GP. Advances in biochemical mechanisms of diabetic retinopathy. Eur Rev Med Pharmacol Sci. 2007; 11(3): 115 - 163.

[344] Дедов И.И., Шестакова М.В., Викулова О.К., и др. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021; 24(3): 204 - 221. doi: 10.14341/DM12759

[345] Porta M, Kohner E. Screening for Diabetic Retinopathy in Europe. Diabet Med. 1991; 8(3): 197 - 198. doi: 10.1111/j.1464-5491.1991.tb01571.x

[346] Early Treatment Diabetic Retinopathy Study Research Group. Early Photocoagulation for Diabetic Retinopathy. Ophthalmology. 1991; 98(5): 766 - 785. doi: 10.1016/S0161-6420(13)38011-7

[347] Аветисов С.Э., Егоров Е.А., Мошетова Л.К., и др. Офтальмология: национальное руководство. 2-ое изд. Москва: ГЭОТАР-Медиа, 2018

[348] Neroev VV, Astakhov YS, Korotkih SA, et al. Protocol of intravitreal drug delivery. Consensus of the Expert Counsil of Retina and Optic Nerve Diseases of the All-Russian Public Organasation "Association of Ophthalmologists". Vestn oftal'mologii. 2020; 136(6): 251. doi: 10.17116/oftalma2020136062251

[349] International Diabetes Federation and The Fred Hollows Foundation. Diabetes eye health: A guide for health care professionals. Brussels: International Diabetes Federation, www.idf.org/eyecare (2015)

[350] American Academy of Ophthalmology. Comprehensive Adult Medical Eye Evaluation Preferred Practice . 2020

[351] Mohamed Q, Gillies MC, Wong TY. Management of Diabetic Retinopathy: a systematic review. JAMA. 2007; 298(8): 902 - 916. doi: 10.1001/jama.298.8.902

[352] Kohner EM, Stratton IM, Aldington SJ, et al. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med. 2001; 18(3): 178 - 184. doi: 10.1046/j.1464-5491.2001.00458.x

[353] Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000; 23 (Suppl 2): B21 - B29.

[354] Matthews DR, Stratton IM, Aldington SJ, et al. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol. 2004; 122(11): 1631 - 1640. doi: 10.1001/archopht.122.11.1631

[355] Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000; 23 (Suppl 2): B54 - B64.

[356] Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002; 61(3): 1086 - 1097. doi: 10.1046/j.1523-1755.2002.00213.x

[357] ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363(3): 233 - 244. doi: 10.1056/NEJMoa1001288

[358] Do D V, Wang X, Vedula SS, et al. Blood pressure control for diabetic retinopathy. Cochrane database Syst Rev. 2015; 1CD006127. doi: 10.1002/14651858.CD006127.pub2

[359] Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017; 237(4): 185 - 222. doi: 10.1159/000458539

[360] Mayer-Davis EJ, Bell RA, Reboussin BA, et al. Antioxidant nutrient intake and diabetic retinopathy. Ophthalmology. 1998; 105(12): 2264 - 2270. doi: 10.1016/S0161-6420(98)91227-1

[361] Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol (Chicago, Ill 1960). 1985; 103(12): 1796 - 1806.

[362] Бровкина А.Ф., Астахов Ю.С. (ред). Руководство по клинической офтальмологии. Москва: Медицинское информационное агентство, 2014

[363] Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice . Ophthalmology. 2020; 127(1): P66 - P145. doi: 10.1016/j.ophtha.2019.09.025

[364] Standards of Medical Care in Diabetes-2021 Abridged for Primary Care Providers. Clin Diabetes. 2021; 39(1): 14 - 43. doi: 10.2337/cd21-as01

[365] Moutray T, Evans JR, Lois N, et al. Different lasers and techniques for proliferative diabetic retinopathy. Cochrane database Syst Rev. 2018; 3CD012314. doi: 10.1002/14651858.CD012314.pub2

[366] 14. Diabetic Retinopathy Study Research Group. Report No 14. Indications for photocoagulation treatment of diabetic retinopathy//Int. Ophthalmol. Clin. - 1987. - V. 27. - P. 239 - 252.

[367] Gross JG, Glassman AR, Jampol LM, et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy. JAMA. 2015; 314(20): 2137 - 2146. doi: 10.1001/jama.2015.15217

[368] Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology. 1981; 88(7): 583 - 600.

[369] Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane database Syst Rev. 2014(11): CD011234. doi: 10.1002/14651858.CD011234.pub2

[370] Elman MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results. Ophthalmology. 2015; 122(2): 375 - 381. doi: 10.1016/j.ophtha.2014.08.047

[371] Do D V, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012; 119(8): 1658 - 1665. doi: 10.1016/j.ophtha.2012.02.010

[372] Boyer DS, Yoon YH, Belfort R, et al. Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema. Ophthalmology. 2014; 121(10): 1904 - 1914. doi: 10.1016/j.ophtha.2014.04.024

[373] World Health Organization. Prevention of blindness from diabetes mellitus. Report of a WHO consultation. Geneva, 2006

[374] Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016; 123(6): 1351 - 1359. doi: 10.1016/j.ophtha.2016.02.022

[375] Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14): 977 - 986. doi: 10.1056/NEJM199309303291401

[376] 'Управление плановой госпитализацией в многопрофильной больнице. Методические рекомендации N 2001/144' (утв. Минздравом РФ 09.11.2001)

[377] Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372(13): 1193 - 1203. doi: 10.1056/NEJMoa1414264

[378] Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012; 15(2): 171 - 185. doi: 10.1007/s10456-011-9249-6

[379] Flynn HW, Chew EY, Simons BD, et al. Pars Plana Vitrectomy in the Early Treatment Diabetic Retinopathy Study. Ophthalmology. 1992; 99(9): 1351 - 1357. doi: 10.1016/S0161-6420(92)31779-8

[380] Early Vitrectomy for Severe Proliferative Diabetic Retinopathy in Eyes with Useful Vision. Ophthalmology. 1988; 95(10): 1307 - 1320. doi: 10.1016/S0161-6420(88)33015-0

[381] Thompson JT, de Bustros S, Michels RG, et al. Results and Prognostic Factors in Vitrectomy for Diabetic Traction Retinal Detachment of the Macula. Arch Ophthalmol. 1987; 105(4): 497 - 502. doi: 10.1001/archopht.1987.01060040067035

[382] Misra A, Bachmann MO, Greenwood RH, et al. Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programme. Diabet Med. 2009; 26(10): 1040 - 1047. doi: 10.1111/j.1464-5491.2009.02820.x

[383] Piyasena MMPN, Murthy GVS, Yip JLY, et al. Systematic review and meta-analysis of diagnostic accuracy of detection of any level of diabetic retinopathy using digital retinal imaging. Syst Rev. 2018; 7(1): 182. doi: 10.1186/s13643-018-0846-y

[384] Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(1): 136 - 154. doi: 10.2337/dc16-2042

[385] Дедов И.И., Шестакова М.В. Осложнения сахарного диабета: лечение и профилактика. Москва: МИА, 2017

[386] Старостина Е.Г. Диабетическая нейропатия: некоторые вопросы дифференциальной диагностики и системной терапии болевого синдрома. РМЖ. 2017(22): 1665 - 1676.

[387] Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain. 2015; 138(1): 43 - 52. doi: 10.1093/brain/awu307

[388] Callaghan BC, Kerber KA, Lisabeth LL, et al. Role of Neurologists and Diagnostic Tests on the Management of Distal Symmetric Polyneuropathy. JAMA Neurol. 2014; 71(9): 1143 - 1149. doi: 10.1001/jamaneurol.2014.1279

[389] Dyck PJ, Albers JW, Andersen H, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011; 27(7): 620 - 628. doi: 10.1002/dmrr.1226

[390] Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for Diabetic Polyneuropathy. Diabetes Care. 2002; 25(11): 2048 - 2052. doi: 10.2337/diacare.25.11.2048

[391] Bastyr EJ, Price KL, Bril V, et al. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther. 2005; 27(8): 1278 - 1294. doi: 10.1016/j.clinthera.2005.08.002

[392] Xiong Q, Lu B, Ye H, et al. The Diagnostic Value of Neuropathy Symptom and Change Score, Neuropathy Impairment Score and Michigan Neuropathy Screening Instrument for Diabetic Peripheral Neuropathy. Eur Neurol. 2015; 74(5-6): 323 - 327. doi: 10.1159/000441449

[393] Meijer JWG, Smit AJ, Sonderen E V., et al. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. Diabet Med. 2002; 19(11): 962 - 965. doi: 10.1046/j.1464-5491.2002.00819.x

[394] Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010; 376(9739): 419 - 430. doi: 10.1016/S0140-6736(10)60576-4

[395] Pop-Busui R, Lu J, Brooks MM, et al. Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care. 2013; 36(10): 3208 - 3215. doi: 10.2337/dc13-0012

[396] Jaiswal M, Lauer A, Martin CL, et al. Peripheral Neuropathy in Adolescents and Young Adults With Type 1 and Type 2 Diabetes From the SEARCH for Diabetes in Youth Follow-up Cohort: A pilot study. Diabetes Care. 2013; 36(12): 3903 - 3908. doi: 10.2337/dc13-1213

[397] Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006; 108(5): 477 - 481. doi: 10.1016/j.clineuro.2005.08.003

[398] Young MJ, Boulton AJ, MacLeod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993; 36(2): 150 - 154.

[399] Spallone V, Morganti R, D'Amato C, et al. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med. 2012; 29(5): 578 - 585. doi: 10.1111/j.1464-5491.2011.03500.x

[400] Pham H, Armstrong DG, Harvey C, et al. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care. 2000; 23(5): 606 - 611. doi: 10.2337/diacare.23.5.606

[401] Apfel SC, Asbury AK, Bril V, et al. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci. 2001; 189(1-2): 3 - 5.

[402] Kim Y, Kim H, Choi S, et al. Clinical Usefulness of the Two-site Semmes-Weinstein Monofilament Test for Detecting Diabetic Peripheral Neuropathy. J Korean Med Sci. 2003; 18(1): 103 - 107. doi: 10.3346/jkms.2003.18.1.103

[403] Perkins BA, Olaleye D, Zinman B, et al. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001; 24(2): 250 - 256. doi: 10.2337/diacare.24.2.250

[404] Perkins BA, Orszag A, Ngo M, et al. Prediction of incident diabetic neuropathy using the monofilament examination: a 4-year prospective study. Diabetes Care. 2010; 33(7): 1549 - 1554. doi: 10.2337/dc09-1835

[405] Dyck PJ, Overland CJ, Low PA, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve. 2010; 42(2): 157 - 164. doi: 10.1002/mus.21661

[406] Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010; 33(10): 2285 - 2293. doi: 10.2337/dc10-1303

[407] Feldman EL, Stevens MJ, Thomas PK, et al. A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy. Diabetes Care. 1994; 17(11): 1281 - 1289. doi: 10.2337/diacare.17.11.1281

[408] Singleton JR, Smith AG, Bromberg MB. Increased Prevalence of Impaired Glucose Tolerance in Patients With Painful Sensory Neuropathy. Diabetes Care. 2001; 24(8): 1448 - 1453. doi: 10.2337/diacare.24.8.1448

[409] Bongaerts BWC, Rathmann W, Heier M, et al. Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy: the KORA F4 study. Diabetes Care. 2013; 36(5): 1141 - 1146. doi: 10.2337/dc12-0744

[410] Ang L, Jaiswal M, Martin C, et al. Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials. Curr Diab Rep. 2014; 14(9): 528. doi: 10.1007/s11892-014-0528-7

[411] Balducci S, Iacobellis G, Parisi L, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006; 20(4): 216 - 223. doi: 10.1016/j.jdiacomp.2005.07.005

[412] Chantelau EA, G. Is the Eichenholtz classification still valid for the diabetic Charcot foot? Swiss Med Wkly. 2014; 144w13948. doi: 10.4414/smw.2014.13948

[413] Удовиченко О.В., Бублик Е.В., Максимова Н.В., и др. Эффективность иммобилизирующих разгрузочных повязок Total Contact Cast: обзор зарубежных рандомизированных клинических исследований и собственные данные. Сахарный диабет. 2010; 13(2): 50 - 55. doi: 10.14341/2072-0351-5674

[414] Molines L, Darmon P, Raccah D. Charcot's foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes Metab. 2010; 36(4): 251 - 255. doi: 10.1016/j.diabet.2010.04.002

[415] Chantelau EA, Richter A. The acute diabetic Charcot foot managed on the basis of magnetic resonance imaging - a review of 71 cases. Swiss Med Wkly. 2013; 143w13831. doi: 10.4414/smw.2013.13831

[416] Schaper NC, Apelqvist J, Bakker K. Reducing lower leg amputations in diabetes: a challenge for patients, healthcare providers and the healthcare system. Diabetologia. 2012; 55(7): 1869 - 1872. doi: 10.1007/s00125-012-2588-z

[417] Snyder RJ, Kirsner RS, Warriner RA, et al. Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Manage. 2010; 56(4 Suppl): S1 - 24.

[418] Noguerol T, Luna A, LS, et al. Advanced MR Imaging Techniques for Differentiation of Neuropathic Arthropathy and Osteomyelitis in the Diabetic Foot. RadioGraphics. 2017; 37(4): 1161 - 1180. doi: 10.1148/rg.2017160101

[419] Ertugrul BM, Lipsky BA, Savk O. Osteomyelitis or Charcot neuro-osteoarthropathy? Differentiating these disorders in diabetic patients with a foot problem. Diabet Foot Ankle. 2013; 4(1): 21855. doi: 10.3402/dfa.v4i0.21855

[420] Christensen TM, Gade-Rasmussen B, Pedersen LW, et al. Duration of off-loading and recurrence rate in Charcot osteo-arthropathy treated with less restrictive regimen with removable walker. J Diabetes Complications. 2012; 26(5): 430 - 434. doi: 10.1016/j.jdiacomp.2012.05.006

[421] Game FL, Catlow R, Jones GR, et al. Audit of acute Charcot's disease in the UK: the CDUK study. Diabetologia. 2012; 55(1): 32 - 35. doi: 10.1007/s00125-011-2354-7

[422] Fernando M, Crowther R, Lazzarini P, et al. Biomechanical characteristics of peripheral diabetic neuropathy: A systematic review and meta-analysis of findings from the gait cycle, muscle activity and dynamic barefoot plantar pressure. Clin Biomech. 2013; 28(8): 831 - 845. doi: 10.1016/j.clinbiomech.2013.08.004

[423] Schaper NC, Netten JJ, Apelqvist J, et al. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev. 2020; 36(S1): e3266. doi: 10.1002/dmrr.3266

[424] Cavanagh PR, Bus SA. Off-loading the diabetic foot for ulcer prevention and healing. Plast Reconstr Surg. 2011; 127 Suppl 248S - 256S. doi: 10.1097/PRS.0b013e3182024864

[425] Nilsson PM, Cederholm J, Zethelius BR, et al. Trends in blood pressure control in patients with type 2 diabetes: data from the Swedish National Diabetes Register (NDR). Blood Press. 2011; 20(6): 348 - 354. doi: 10.3109/08037051.2011.587288

[426] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021 - 3104. doi: 10.1093/eurheartj/ehy339

[427] Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Pr. Hypertension. 2018; 71(6): e13 - e115. doi: 10.1161/HYP.0000000000000065

[428] Pickering TG, Hall JE, Appel LJ, et al. Recommendations for Blood Pressure Measurement in Humans and Experimental Animals. Hypertension. 2005; 45(1): 142 - 161. doi: 10.1161/01.HYP.0000150859.47929.8e

[429] Powers BJ, Olsen MK, Smith VA, et al. Measuring blood pressure for decision making and quality reporting: where and how many measures? Ann Intern Med. 2011; 154(12): 781 - 788. doi: 10.7326/0003-4819-154-12-201106210-00005

[430] de Boer IH, Bangalore S, Benetos A, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(9): 1273 - 1284. doi: 10.2337/dci17-0026

[431] Bobrie G, N, Vaur L, et al. Is 'isolated home' hypertension as opposed to 'isolated office' hypertension a sign of greater cardiovascular risk? Arch Intern Med. 2001; 161(18): 2205 - 2211.

[432] Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005; 111(14): 1777 - 1783. doi: 10.1161/01.CIR.0000160923.04524.5B

[433] Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane database Syst Rev. 2013(10): CD008277. doi: 10.1002/14651858.CD008277.pub2

[434] M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016; 352i717. doi: 10.1136/bmj.i717

[435] Bulugahapitiya U, Siyambalapitiya S, Sithole J, et al. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009; 26(2): 142 - 148. doi: 10.1111/j.1464-5491.2008.02640.x

[436] Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006; 24(2): 215 - 233. doi: 10.1097/01.hjh.0000199800.72563.26

[437] Pimenta E, Gaddam KK, Oparil S, et al. Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant Hypertension. Hypertension. 2009; 54(3): 475 - 481. doi: 10.1161/HYPERTENSIONAHA.109.131235

[438] Sofi F, Abbate R, Gensini GF, et al. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010; 92(5): 1189 - 1196. doi: 10.3945/ajcn.2010.29673

[439] Flegal KM, Kit BK, Orpana H, et al. Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories. JAMA. 2013; 309(1): 71 - 82. doi: 10.1001/jama.2012.113905

[440] Cushman WC, Cutler JA, Hanna E, et al. Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure. Arch Intern Med. 1998; 158(11): 1197 - 1207.

[441] Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ. 1994; 309(6959): 901 - 911. doi: 10.1136/bmj.309.6959.901

[442] Cornelissen VA, Fagard RH, Coeckelberghs E, et al. Impact of Resistance Training on Blood Pressure and Other Cardiovascular Risk Factors. Hypertension. 2011; 58(5): 950 - 958. doi: 10.1161/HYPERTENSIONAHA.111.177071

[443] Bakris GL, Weir MR, Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003; 5(3): 202 - 209.

[444] Webster R, Salam A, de Silva HA, et al. Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial. JAMA. 2018; 320(6): 566 - 579. doi: 10.1001/jama.2018.10359

[445] Barzilay JI, Davis BR, Bettencourt J, et al. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich). 2004; 6(3): 116 - 125.

[446] Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010; 56(1): 77 - 85. doi: 10.1016/j.jacc.2010.02.046

[447] Чазова И.Е., Мычка В.Б. Новые возможности в лечении больных с метаболическим синдромом: результаты исследования ALMAZ. Системные гипертензии. 2006(2): 14 - 17.

[448] Chazova I, Schlaich MP. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens. 2013; 20131 - 9. doi: 10.1155/2013/541689

[449] Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407 - 477. doi: 10.1093/eurheartj/ehz425

[450] Underwood SR, Anagnostopoulos C, Cerqueira M, et al. Myocardial perfusion scintigraphy: the evidence. Eur J Nucl Med Mol Imaging. 2004; 31(2): 261 - 291. doi: 10.1007/s00259-003-1344-5

[451] Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. Epub ahead of print 31 August 2019. DOI: 10.1093/eurheartj/ehz486

[452] Bax JJ, Young LH, Frye RL, et al. Screening for coronary artery disease in patients with diabetes. Diabetes Care. 2007; 30(10): 2729 - 2736. doi: 10.2337/dc07-9927

[453] Meyers DG, Neuberger JS, He J. Cardiovascular Effect of Bans on Smoking in Public Places. J Am Coll Cardiol. 2009; 54(14): 1249 - 1255. doi: 10.1016/j.jacc.2009.07.022

[454] World Health Organization. IARC Handbooks of Cancer Prevention, Tobacco Control, vol. 14: Effectiveness of Tax and Price Policies for Tobacco Control. Lyon, 2011

[455] Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane database Syst Rev. 2004(1): CD003041. doi: 10.1002/14651858.CD003041.pub2

[456] Estruch R, Ros E, J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med. 2013; 368(14): 1279 - 1290. doi: 10.1056/NEJMoa1200303

[457] Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 1988; 260(14): 2088 - 2093.

[458] Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26(3): 215 - 225. doi: 10.1093/eurheartj/ehi115

[459] Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37(39): 2999 - 3058. doi: 10.1093/eurheartj/ehw272

[460] Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018; 137(15): 1571 - 1582. doi: 10.1161/CIRCULATIONAHA.117.030950

[461] Zhang X-L, Zhu Q-Q, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015; 13(1): 123. doi: 10.1186/s12916-015-0358-8

[462] ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17): 1563 - 1574. doi: 10.1056/NEJMoa1001282

[463] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Russ J Cardiol. 2020; 25(5): 3826. doi: 10.15829/1560-4071-2020-3826

[464] Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366(9500): 1849 - 1861. doi: 10.1016/S0140-6736(05)67667-2

[465] Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71 - 86. doi: 10.1136/bmj.324.7329.71

[466] S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992; 340(8833): 1421 - 1425. doi: 10.1016/0140-6736(92)92619-q

[467] Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018; 39(3): 213 - 260. doi: 10.1093/eurheartj/ehx419

[468] ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018; 379(16): 1529 - 1539. doi: 10.1056/NEJMoa1804988

[469] Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019; 394(10204): 1169 - 1180. doi: 10.1016/S0140-6736(19)31887-2

[470] Anand SS, Eikelboom JW, Dyal L, et al. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. J Am Coll Cardiol. 2019; 73(25): 3271 - 3280. doi: 10.1016/j.jacc.2019.02.079

[471] BARI 2D Study Group, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009; 360(24): 2503 - 2515. doi: 10.1056/NEJMoa0805796

[472] Abdallah MS, Wang K, Magnuson EA, et al. Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. JAMA. 2013; 310(15): 1581 - 1590. doi: 10.1001/jama.2013.279208

[473] Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87 - 165. doi: 10.1093/eurheartj/ehy394

[474] Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016; 37(3): 267 - 315. doi: 10.1093/eurheartj/ehv320

[475] Senthinathan A, Kelly V, Dzingina M, et al. Hyperglycaemia in acute coronary syndromes: summary of NICE guidance. BMJ. 2011; 343d6646. doi: 10.1136/bmj.d6646

[476] Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013; 36(5): 1304 - 1311. doi: 10.2337/dc12-0719

[477] Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018; 39(2): 119 - 177. doi: 10.1093/eurheartj/ehx393

[478] Hernandez A V., Usmani A, Rajamanickam A, et al. Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus. Am J Cardiovasc Drugs. 2011; 11(2): 115 - 128. doi: 10.2165/11587580-000000000-00000

[479] Komajda M, McMurray JJV, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010; 31(7): 824 - 831. doi: 10.1093/eurheartj/ehp604

[480] Мареев В.Ю., Фомин И.В., Агеев Ф.Т., и др. Сердечная недостаточность: хроническая и острая декомпенсированная. Диагностика, профилактика и лечение. Кардиология. 2018; 58(6S): 8 - 158. doi: 10.18087/cardio.2475

[481] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2017; 70(6): 776 - 803. doi: 10.1016/j.jacc.2017.04.025

[482] Wiviott SD, Raz I, Bonaca MP, et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018; 20083 - 89. doi: 10.1016/j.ahj.2018.01.012

[483] McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381(21): 1995 - 2008. doi: 10.1056/NEJMoa1911303

[484] McMurray JJV, DeMets DL, Inzucchi SE, et al. A trial to evaluate the effect of the sodium-glucose co transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA HF). Eur J Heart Fail. 2019; 21(5): 665 - 675. doi: 10.1002/ejhf.1432

[485] Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15): 1413 - 1424. doi: 10.1056/NEJMoa2022190

[486] Eurich DT, Weir DL, Majumdar SR, et al. Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure. Circ Hear Fail. 2013; 6(3): 395 - 402. doi: 10.1161/CIRCHEARTFAILURE.112.000162

[487] Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015; 373(23): 2247 - 2257. doi: 10.1056/NEJMoa1509225

[488] Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(13): 1228 - 1239. doi: 10.1056/NEJMoa1612917

[489] Azoulay L, Suissa S. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies. Diabetes Care. 2017; 40(5): 706 - 714. doi: 10.2337/dc16-1943

[490] Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005; 111(5): 583 - 590. doi: 10.1161/01.CIR.0000154542.13412.B1

[491] Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005; 28(10): 2345 - 2351. doi: 10.2337/diacare.28.10.2345

[492] Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013; 369(14): 1317 - 1326. doi: 10.1056/NEJMoa1307684

[493] Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015; 385(9982): 2067 - 2076. doi: 10.1016/S0140-6736(14)62225-X

[494] Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015; 373(3): 232 - 242. doi: 10.1056/NEJMoa1501352

[495] Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019; 321(1): 69 - 79. doi: 10.1001/jama.2018.18269

[496] Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007; 50(1): 18 - 25. doi: 10.1007/s00125-006-0491-1

[497] Morbach S, Furchert H, U, et al. Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade. Diabetes Care. 2012; 35(10): 2021 - 2027. doi: 10.2337/dc12-0200

[498] National Institute for Health and Clinical Excellence. Diabetic Foot Problems. Inpatient management of diabetic foot problems. London, 2011

[499] Edmonds ME, Morrison N, Laws JW, et al. Medial arterial calcification and diabetic neuropathy. BMJ. 1982; 284(6320): 928 - 930. doi: 10.1136/bmj.284.6320.928

[500] Feinglass J, Shively VP, Martin GJ, et al. How 'preventable' are lower extremity amputations? A qualitative study of patient perceptions of precipitating factors. Disabil Rehabil. 2012; 34(25): 2158 - 2165. doi: 10.3109/09638288.2012.677936

[501] Sumpio BE, Armstrong DG, Lavery LA, et al. The role of interdisciplinary team approach in the management of the diabetic foot: a joint statement from the Society for Vascular Surgery and the American Podiatric Medical Association. J Vasc Surg. 2010; 51(6): 1504 - 1506. doi: 10.1016/j.jvs.2010.04.010

[502] Ababneh M, Al Ayed MY, Robert AA, et al. Clinical Utility of the Ankle-Brachial Index and Toe Brachial Index in Patients with Diabetic Foot Ulcers. Curr Diabetes Rev.; 15. Epub ahead of print 31 May 2019. DOI: 10.2174/1573399815666190531093238

[503] Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Int Angiol. 2000; 19(1 Suppl 1): 1 - 304.

[504] Huen KH, Chowdhury R, Shafii SM, et al. Smoking Cessation Is the Least Successful Outcome of Risk Factor Modification in Uninsured Patients with Symptomatic Peripheral Arterial Disease. Ann Vasc Surg. 2015; 29(1): 42 - 49. doi: 10.1016/j.avsg.2014.09.014

[505] The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733): 2215 - 2222. doi: 10.1016/S0140-6736(10)60484-9

[506] Rickels MR, Mueller R, Teff KL, et al. secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. J Clin Endocrinol Metab. 2010; 95(3): 1238 - 1246. doi: 10.1210/jc.2009-2289

[507] Российское общество ангиологов и сосудистых хирургов, Ассоциация сердечно-сосудистых хирургов России, Российское научное общество рентгенэндоваскулярных хирургов и интервенционных радиологов, et al. Национальные рекомендации по ведению пациентов с заболеваниями артерий нижних конечностей. Москва, 2013

[508] Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representati. G Ital Cardiol (Rome). 2017; 18(7): 547 - 612. doi: 10.1714/2729.27821

[509] Schaper NC, van Netten JJ, Apelqvist J, et al. IWGDF Guidelines on the prevention and management of diabetic foot disease. 2019

[510] Mills JL, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: Risk stratification based on Wound, Ischemia, and foot Infection (WIfI). J Vasc Surg. 2014; 59(1): 220 - 234. e2. doi: 10.1016/j.jvs.2013.08.003

[511] Collins R, Burch J, Cranny G, et al. Duplex ultrasonography, magnetic resonance angiography, and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review. BMJ. 2007; 334(7606): 1257. doi: 10.1136/bmj.39217.473275.55

[512] Dominguez A, Bahadorani J, Reeves R, et al. Endovascular therapy for critical limb ischemia. Expert Rev Cardiovasc Ther. 2015; 13(4): 429 - 444. doi: 10.1586/14779072.2015.1019472

[513] Manzi M, Palena L, Cester G. Endovascular techniques for limb salvage in diabetics with crural and pedal disease. J Cardiovasc Surg (Torino). 2011; 52(4): 485 - 492.

[514] Belch JJF, Dormandy J. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010; 52(4): 825 - 833. e2. doi: 10.1016/j.jvs.2010.04.027

[515] Cacoub PP, Bhatt DL, Steg PG, et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2008; 30(2): 192 - 201. doi: 10.1093/eurheartj/ehn534

[516] Aboyans V, Ricco J-B, Bartelink M-LEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9): 763 - 816. doi: 10.1093/eurheartj/ehx095

[517] Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391(10117): 219 - 229. doi: 10.1016/S0140-6736(17)32409-1

[518] Kronlage M, Blessing E, OJ, et al. Anticoagulation in addition to dual antiplatelet therapy has no impact on long-term follow-up after endovascular treatment of (sub)acute lower limb ischemia. Vasa. 2019; 48(4): 321 - 329. doi: 10.1024/0301-1526/a000786

[519] Monteiro-Soares M, Boyko EJ, Ribeiro J, et al. Predictive factors for diabetic foot ulceration: a systematic review. Diabetes Metab Res Rev. 2012; 28(7): 574 - 600. doi: 10.1002/dmrr.2319

[520] Crawford F, Cezard G, Chappell FM, et al. A systematic review and individual patient data meta-analysis of prognostic factors for foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS). Health Technol Assess (Rockv). 2015; 19(57): 1 - 210. doi: 10.3310/hta19570

[521] Monteiro Soares M, Russell D, Boyko EJ, et al. Guidelines on the classification of diabetic foot ulcers (IWGDF 2019). Diabetes Metab Res Rev. 2020; 36(S1): e3273. doi: 10.1002/dmrr.3273

[522] Mayor J, Chung J, Zhang Q, et al. Using the Society for Vascular Surgery Wound, Ischemia, and foot Infection classification to identify patients most likely to benefit from revascularization. J Vasc Surg. 2019; 70(3): 776 - 785.e1. doi: 10.1016/j.jvs.2018.11.039

[523] Hinchliffe RJ, Forsythe RO, Apelqvist J, et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020; 36 Suppl 1e3276. doi: 10.1002/dmrr.3276

[524] Ndosi M, Wright-Hughes A, Brown S, et al. Prognosis of the infected diabetic foot ulcer: a 12-month prospective observational study. Diabet Med. 2018; 35(1): 78 - 88. doi: 10.1111/dme.13537

[525] Tan T-W, Shih C-D, Concha-Moore KC, et al. Disparities in outcomes of patients admitted with diabetic foot infections. PLoS One. 2019; 14(2): e0211481. doi: 10.1371/journal.pone.0211481

[526] Zha M-L, Cai J-Y, Chen H-L. A Bibliometric Analysis of Global Research Production Pertaining to Diabetic Foot Ulcers in the Past Ten Years. J Foot Ankle Surg. 2019; 58(2): 253 - 259. doi: 10.1053/j.jfas.2018.08.052

[527] Peters EJG, Lipsky BA. Diagnosis and management of infection in the diabetic foot. Med Clin North Am. 2013; 97(5): 911 - 946. doi: 10.1016/j.mcna.2013.04.005

[528] Lavery LA, Peters EJG, Armstrong DG, et al. Risk factors for developing osteomyelitis in patients with diabetic foot wounds. Diabetes Res Clin Pract. 2009; 83(3): 347 - 352. doi: 10.1016/j.diabres.2008.11.030

[529] Sotto A, Richard J-L, Jourdan N, et al. Miniaturized Oligonucleotide Arrays. Diabetes Care. 2007; 30(8): 2051 - 2056. doi: 10.2337/dc07-0461

[530] Senneville , Lipsky BA, Abbas ZG, et al. Diagnosis of infection in the foot in diabetes: a systematic review. Diabetes Metab Res Rev. 2020; 36(S1): e3281. doi: 10.1002/dmrr.3281

[531] Peters EJG, Lipsky BA, Senneville , et al. Interventions in the management of infection in the foot in diabetes: a systematic review. Diabetes Metab Res Rev. 2020; 36(S1): e3282. doi: 10.1002/dmrr.3282

[532] Senneville E, Melliez H, Beltrand E, et al. Culture of Percutaneous Bone Biopsy Specimens For Diagnosis of Diabetic Foot Osteomyelitis: Concordance With Ulcer Swab Cultures. Clin Infect Dis. 2006; 42(1): 57 - 62. doi: 10.1086/498112

[533] Ertugrul MB, Baktiroglu S, Salman S, et al. Pathogens Isolated From Deep Soft Tissue and Bone in Patients With Diabetic Foot Infections. J Am Podiatr Med Assoc. 2008; 98(4): 290 - 295. doi: 10.7547/0980290

[534] Noor S, Raghav A, Parwez I, et al. Molecular and culture based assessment of bacterial pathogens in subjects with diabetic foot ulcer. Diabetes Metab Syndr Clin Res Rev. 2018; 12(3): 417 - 421. doi: 10.1016/j.dsx.2018.03.001

[535] Percival SL, Malone M, Mayer D, et al. Role of anaerobes in polymicrobial communities and biofilms complicating diabetic foot ulcers. Int Wound J. 2018; 15(5): 776 - 782. doi: 10.1111/iwj.12926

[536] FJ, JL, E, et al. Cortical disruption is the most reliable and accurate plain radiographic sign in the diagnosis of diabetic foot osteomyelitis. Diabet Med. 2019; 36(2): 258 - 259. doi: 10.1111/dme.13824

[537] O'Meara S, Nelson EA, Golder S, et al. Systematic review of methods to diagnose infection in foot ulcers in diabetes. Diabet Med. 2006; 23(4): 341 - 347. doi: 10.1111/j.1464-5491.2006.01830.x

[538] Ramanujam CL, Han D, Zgonis T. Medical Imaging and Laboratory Analysis of Diagnostic Accuracy in 107 Consecutive Hospitalized Patients With Diabetic Foot Osteomyelitis and Partial Foot Amputations. Foot Ankle Spec. 2018; 11(5): 433 - 443. doi: 10.1177/1938640017750255

[539] Dinh MT, Abad CL, Safdar N. Diagnostic Accuracy of the Physical Examination and Imaging Tests for Osteomyelitis Underlying Diabetic Foot Ulcers: Meta Analysis. Clin Infect Dis. 2008; 47(4): 519 - 527. doi: 10.1086/590011

[540] Cohen M, Cerniglia B, Gorbachova T, et al. Added value of MRI to X-ray in guiding the extent of surgical resection in diabetic forefoot osteomyelitis: a review of pathologically proven, surgically treated cases. Skeletal Radiol. 2019; 48(3): 405 - 411. doi: 10.1007/s00256-018-3045-y

[541] Lauri C, Tamminga M, Glaudemans AWJM, et al. Detection of Osteomyelitis in the Diabetic Foot by Imaging Techniques: A Systematic Review and Meta-analysis Comparing MRI, White Blood Cell Scintigraphy, and FDG-PET. Diabetes Care. 2017; 40(8): 1111 - 1120. doi: 10.2337/dc17-0532

[542] Weinstein D, Wang A, Chambers R, et al. Evaluation of Magnetic Resonance Imaging in the Diagnosis of Osteomyelitis in Diabetic Foot Infections. Foot Ankle. 1993; 14(1): 18 - 22. doi: 10.1177/107110079301400104

[543] Bus SA. The Role of Pressure Offloading on Diabetic Foot Ulcer Healing and Prevention of Recurrence. Plast Reconstr Surg. 2016; 138(3 Suppl): 179S - 187S. doi: 10.1097/PRS.0000000000002686

[544] Fernando ME, Crowther RG, Pappas E, et al. Plantar Pressure in Diabetic Peripheral Neuropathy Patients with Active Foot Ulceration, Previous Ulceration and No History of Ulceration: A Meta-Analysis of Observational Studies. PLoS One. 2014; 9(6): e99050. doi: 10.1371/journal.pone.0099050

[545] Jeffcoate W, Game F, Turtle-Savage V, et al. Evaluation of the effectiveness and cost-effectiveness of lightweight fibreglass heel casts in the management of ulcers of the heel in diabetes: a randomised controlled trial. Health Technol Assess (Rockv). 2017; 21(34): 1 - 92. doi: 10.3310/hta21340

[546] Piaggesi A, Goretti C, Iacopi E, et al. Comparison of Removable and Irremovable Walking Boot to Total Contact Casting in Offloading the Neuropathic Diabetic Foot Ulceration. Foot Ankle Int. 2016; 37(8): 855 - 861. doi: 10.1177/1071100716643429

[547] Bus SA, van Netten JJ, Kottink AI, et al. The efficacy of removable devices to offload and heal neuropathic plantar forefoot ulcers in people with diabetes: a single-blinded multicentre randomised controlled trial. Int Wound J. 2018; 15(1): 65 - 74. doi: 10.1111/iwj.12835

[548] Gordon KA, Lebrun EA, Tomic-Canic M, et al. The role of surgical debridement in healing of diabetic foot ulcers. Skinmed. 2012; 10(1): 24 - 26.

[549] Митиш В.А., Ерошкин И.А., Галстян Г.Р., и др. Гнойно-некротические поражения нейроишемической формы синдрома диабетической стопы. Новые возможности комплексного хирургического лечения. Эндокринная хирургия. 2008; 2(1): 15 - 19. doi: 10.14341/2306-3513-2008-1-15-19

[550] Caputo WJ, Beggs DJ, DeFede JL, et al. A prospective randomised controlled clinical trial comparing hydrosurgery debridement with conventional surgical debridement in lower extremity ulcers. Int Wound J. 2008; 5(2): 288 - 294. doi: 10.1111/j.1742-481X.2007.00490.x

[551] Jeffcoate WJ, Bus SA, Game FL, et al. Reporting standards of studies and papers on the prevention and management of foot ulcers in diabetes: required details and markers of good quality. Lancet Diabetes Endocrinol. 2016; 4(9): 781 - 788. doi: 10.1016/S2213-8587(16) 30012-2

[552] Vas P, Rayman G, Dhatariya K, et al. Effectiveness of interventions to enhance healing of chronic foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2020; 36(S1): e3284. doi: 10.1002/dmrr.3284

[553] Lipsky BA, Senneville , Abbas ZG, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020; 36(S1): e3280. doi: 10.1002/dmrr.3280

[554] Selva Olid A, I, Barajas-Nava LA, et al. Systemic antibiotics for treating diabetic foot infections. Cochrane Database Syst Rev. 2015; 2015(9): CD009061. doi: 10.1002/14651858.CD009061.pub2

[555] Jongsma H, Bekken JA, Akkersdijk GP, et al. Angiosome-directed revascularization in patients with critical limb ischemia. J Vasc Surg. 2017; 65(4): 1208 - 1219.e1. doi: 10.1016/j.jvs.2016.10.100

[556] Lo ZJ, Lin Z, Pua U, et al. Diabetic Foot Limb Salvage-A Series of 809 Attempts and Predictors for Endovascular Limb Salvage Failure. Ann Vasc Surg. 2018; 499 - 16. doi: 10.1016/j.avsg.2018.01.061

[557] Lejay A, Georg Y, Tartaglia E, et al. Long-Term Outcomes of Direct and Indirect Below-The-Knee Open Revascularization Based on the Angiosome Concept in Diabetic Patients with Critical Limb Ischemia. Ann Vasc Surg. 2014; 28(4): 983 - 989. doi: 10.1016/j.avsg.2013.08.026

[558] Hinchliffe RJ, Brownrigg JRW, Andros G, et al. Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review. Diabetes Metab Res Rev. 2016; 32(S1): 136 - 144. doi: 10.1002/dmrr.2705

[559] Capell WH, Bonaca MP, Nehler MR, et al. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018; 19983 - 91. doi: 10.1016/j.ahj.2018.01.011

[560] Raymond Foley T, Singh GD, Kokkinidis DG, et al. High Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease. J Am Heart Assoc. 2017; 6(7): e005699. doi: 10.1161/JAHA.117.005699

[561] Yang Q, Zhang Y, Yin H, et al. Topical Recombinant Human Epidermal Growth Factor for Diabetic Foot Ulcers: A Meta-Analysis of Randomized Controlled Clinical Trials. Ann Vasc Surg. 2020; 62442 - 451. doi: 10.1016/j.avsg.2019.05.041

[562] Berlanga-Acosta J, J, C, et al. Diabetic Foot Ulcers and Epidermal Growth Factor: Revisiting the Local Delivery Route for a Successful Outcome. Biomed Res Int. 2017; 20171 - 10. doi: 10.1155/2017/2923759

[563] Lavery LA, Murdoch DP, Kim PJ, et al. Negative Pressure Wound Therapy With Low Pressure and Gauze Dressings to Treat Diabetic Foot Wounds. J Diabetes Sci Technol. 2014; 8(2): 346 - 349. doi: 10.1177/1932296813519012

[564] Liu Z, Dumville JC, Hinchliffe RJ, et al. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus. Cochrane Database Syst Rev. 2018; 2018(10): CD010318. doi: 10.1002/14651858.CD010318.pub3

[565] Зайцева Е.Л., Доронина Л.П., Молчков Р.В., и др. Влияние терапии отрицательным давлением на репаративные процессы в мягких тканях нижних конечностей у пациентов с нейропатической и нейроишемической формами синдрома диабетической стопы. Сахарный диабет. 2014; 17(3): 113 - 121. doi: 10.14341/DM20143113-121

[566] Bonner T, Foster M, Spears-Lanoix E. Type 2 diabetes-related foot care knowledge and foot self-care practice interventions in the United States: a systematic review of the literature. Diabet Foot Ankle. 2016; 7(1): 29758. doi: 10.3402/dfa.v7.29758

[567] Netten JJ, Raspovic A, Lavery LA, et al. Prevention of foot ulcers in the at risk patient with diabetes: a systematic review. Diabetes Metab Res Rev. 2020; 36(S1): e3270. doi: 10.1002/dmrr.3270

[568] Donohoe ME, Fletton JA, Hook A, et al. Improving foot care for people with diabetes mellitus - a randomized controlled trial of an integrated care approach. Diabet Med. 2000; 17(8): 581 - 587. doi: 10.1046/j.1464-5491.2000.00336.x

[569] Guerin A, Nisenbaum R, Ray JG. Use of Maternal GHb Concentration to Estimate the Risk of Congenital Anomalies in the Offspring of Women with Prepregnancy Diabetes. Diabetes Care. 2007; 30(7): 1920 - 1925. doi: 10.2337/dc07-0278

[570] Lowe LP, Metzger BE, Dyer AR, et al. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: Associations of maternal A1C and glucose with pregnancy outcomes. Diabetes Care. 2012; 35(3): 574 - 580. doi: 10.2337/dc11-1687

[571] Wahabi HA, Alzeidan RA, Bawazeer GA, et al. Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2010; 10(1): 63. doi: 10.1186/1471-2393-10-63

[572] Ray JG, O'Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM. 2001; 94(8): 435 - 444. doi: 10.1093/qjmed/94.8.435

[573] Peterson C, Grosse SD, Li R, et al. Preventable health and cost burden of adverse birth outcomes associated with pregestational diabetes in the United States. Am J Obstet Gynecol. 2015; 212(1): 74.e1 - 74.e9. doi: 10.1016/j.ajog.2014.09.009

[574] Boulot P, Chabbert-Buffet N, D'Ercole C, et al. French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care. 2003; 26(11): 2990 - 2993. doi: 10.2337/diacare.26.11.2990

[575] Ekpebegh CO, Coetzee EJ, van der Merwe L, et al. A 10-year retrospective analysis of pregnancy outcome in pregestational Type 2 diabetes: comparison of insulin and oral glucose-lowering agents. Diabet Med. 2007; 24(3): 253 - 258. doi: 10.1111/j.1464-5491.2007.02053.x

[576] Roland JM, Murphy HR, Ball V, et al. The pregnancies of women with Type 2 diabetes: poor outcomes but opportunities for improvement. Diabet Med. 2005; 22(12): 1774 - 1777. doi: 10.1111/j.1464-5491.2005.01784.x

[577] Pollex EK, Feig DS, Lubetsky A, et al. Insulin Glargine Safety in Pregnancy: A transplacental transfer study. Diabetes Care. 2010; 33(1): 29 - 33. doi: 10.2337/dc09-1045

[578] Holcberg G, Tsadkin-Tamir M, Sapir O, et al. Transfer of insulin lispro across the human placenta. Eur J Obstet Gynecol Reprod Biol. 2004; 115(1): 117 - 118. doi: 10.1016/j.ejogrb.2003.10.006

[579] Boskovic R, Feig DS, Derewlany L, et al. Transfer of Insulin Lispro Across the Human Placenta: In vitro perfusion studies. Diabetes Care. 2003; 26(5): 1390 - 1394. doi: 10.2337/diacare.26.5.1390

[580] Suffecool K, Rosenn B, Niederkofler EE, et al. Insulin Detemir Does Not Cross the Human Placenta. Diabetes Care. 2015; 38(2): e20 - e21. doi: 10.2337/dc14-2090

[581] Bullo M, Tschumi S, Bucher BS, et al. Pregnancy Outcome Following Exposure to Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Antagonists. Hypertension. 2012; 60(2): 444 - 450. doi: 10.1161/HYPERTENSIONAHA.112.196352

[582] Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ. 2015; 350(10): h1035. doi: 10.1136/bmj.h1035

[583] Chew EY, Mills JL, Metzger BE, et al. Metabolic Control and Progression of Retinopathy: The Diabetes in Early Pregnancy Study. Diabetes Care. 1995; 18(5): 631 - 637. doi: 10.2337/diacare.18.5.631

[584] Damm JA, Asbjornsdottir B, Callesen NF, et al. Diabetic Nephropathy and Microalbuminuria in Pregnant Women With Type 1 and Type 2 Diabetes: Prevalence, antihypertensive strategy, and pregnancy outcome. Diabetes Care. 2013; 36(11): 3489 - 3494. doi: 10.2337/dc13-1031

[585] Ringholm L, Damm JA, Vestgaard M, et al. Diabetic Nephropathy in Women With Preexisting Diabetes: From Pregnancy Planning to Breastfeeding. Curr Diab Rep. 2016; 16(2): 12. doi: 10.1007/s11892-015-0705-3

[586] Carr DB, Koontz GL, Gardella C, et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens. 2006; 19(5): 513 - 519. doi: 10.1016/j.amjhyper.2005.12.010

[587] Nevis IF, Reitsma A, Dominic A, et al. Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol. 2011; 6(11): 2587 - 2598. doi: 10.2215/CJN.10841210

[588] O'Neill SM, Kenny LC, Khashan AS, et al. Different insulin types and regimens for pregnant women with pre-existing diabetes. Cochrane database Syst Rev. 2017; 2CD011880. doi: 10.1002/14651858.CD011880.pub2

[589] Simmons D, Thompson CF, Conroy C, et al. Use of Insulin Pumps in Pregnancies Complicated by Type 2 Diabetes and Gestational Diabetes in a Multiethnic Community. Diabetes Care. 2001; 24(12): 2078 - 2082. doi: 10.2337/diacare.24.12.2078

[590] Murphy HR, Roland JM, Skinner TC, et al. Effectiveness of a Regional Prepregnancy Care Program in Women With Type 1 and Type 2 Diabetes: Benefits beyond glycemic control. Diabetes Care. 2010; 33(12): 2514 - 2520. doi: 10.2337/dc10-1113

[591] American Diabetes Association. 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021; 44(Supplement 1): S100 - S110. doi: 10.2337/dc21-S008

[592] Abell SK, Boyle JA, de Courten B, et al. Impact of type 2 diabetes, obesity and glycaemic control on pregnancy outcomes. Aust New Zeal J Obstet Gynaecol. 2017; 57(3): 308 - 314. doi: 10.1111/ajo.12521

[593] Inkster ME, Fahey TP, Donnan PT, et al. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: Systematic review of observational studies. BMC Pregnancy Childbirth. 2006; 6(1): 30. doi: 10.1186/1471-2393-6-30

[594] Wahabi HA, Esmaeil SA, Fayed A, et al. Pre-existing diabetes mellitus and adverse pregnancy outcomes. BMC Res Notes. 2012; 5(1): 496. doi: 10.1186/1756-0500-5-496

[595] Taylor C, McCance DR, Chappell L, et al. Implementation of guidelines for multidisciplinary team management of pregnancy in women with pre-existing diabetes or cardiac conditions: results from a UK national survey. BMC Pregnancy Childbirth. 2017; 17(1): 434. doi: 10.1186/s12884-017-1609-9

[596] Tieu J, Middleton P, Crowther CA, et al. Preconception care for diabetic women for improving maternal and infant health. Cochrane database Syst Rev. 2017; 8CD007776. doi: 10.1002/14651858.CD007776.pub3

[597] Meneilly GS, Knip A, Miller DB, et al. Diabetes in Older People. Can J Diabetes. 2018; 42(Suppl 1): S283 - S295. doi: 10.1016/j.jcjd.2017.10.021

[598] LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019; 104(5): 1520 - 1574. doi: 10.1210/jc.2019-00198

[599] Общероссийская общественная организация 'Российская ассоциация геронтологов и гериатров'. Клинические рекомендации 'Старческая астения'. 2020

[600] Общероссийская общественная организация 'Российское общество психиатров', Общественная организация 'Российская ассоциация геронтологов и гериатров'. Когнитивные расстройства у лиц пожилого и старческого возраста. 2020

[601] International Diabetes Federation Working Group. Managing older people with Type 2 Diabetes. Global Guideline. Brussels: International Diabetes Federation, 2013

[602] Ткачева О.Н., Рунихина Н.К., Остапенко В.С. и др. Валидация опросника для скрининга синдрома старческой астении в амбулаторной практике. Успехи геронтологии. 2017; 30(2): 236 - 242.

[603] American Diabetes Association. 13. Older Adults: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45(Supplement_1): S195 - S207. doi: 10.2337/dc22-S013

[604] Schernthaner G, Barnett AH, Patel S, et al. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged >= 65 years. Diabetes Obes Metab. 2014; 16(11): 1078 - 1086. doi: 10.1111/dom.12321

[605] Round EM, Engel SS, Golm GT, et al. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging. 2014; 31(3): 203 - 214. doi: 10.1007/s40266-014-0155-7

[606] Barnett AH, Huisman H, Jones R, et al. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013; 382(9902): 1413 - 1423. doi: 10.1016/S0140-6736(13)61500-7

[607] Karyekar CS, Ravichandran S, Allen E, et al. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged >= 65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging. 2013; 8419 - 430. doi: 10.2147/CIA.S41246

[608] Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother. 2010; 8(5): 405 - 418. doi: 10.1016/j.amjopharm.2010.10.003

[609] Doucet J, Chacra A, Maheux P, et al. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin. 2011; 27(4): 863 - 869. doi: 10.1185/03007995.2011.554532

[610] Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013; 15(10): 906 - 914. doi: 10.1111/dom.12102

[611] Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996; 44(7): 751 - 755. doi: 10.1111/j.1532-5415.1996.tb03729.x

[612] Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997; 157(15): 1681 - 1686.

[613] Greco D, Pisciotta M, Gambina F, et al. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol diabetes. 2010; 118(4): 215 - 219. doi: 10.1055/s-0029-1241823

[614] Chilcott J, Tappenden P, Jones ML, et al. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther. 2001; 23(11): 1792 - 1823.

[615] Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009; 180(1): 32 - 39. doi: 10.1503/cmaj.080486

[616] Приказ Министерства здравоохранения РФ от 21 марта 2014 г. N 125н 'Об утверждении национального календаря профилактических прививок и календаря профилактических прививок по эпидемическим показаниям' (с изменениями и дополнениями)

[617] Приказ Министерства здравоохранения Российской Федерации от 14.09.2020 N 967н "О внесении изменения в приложение N 1 к приказу Министерства здравоохранения Российской Федерации от 21 марта 2014 г. N 125н "Об утверждении национального календаря профилактич<...>

[618] Goeijenbier M, van Sloten TT, Slobbe L, et al. Benefits of flu vaccination for persons with diabetes mellitus: A review. Vaccine. 2017; 35(38): 5095 - 5101. doi: 10.1016/j.vaccine.2017.07.095

[619] Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet. 2000; 355(9198): 93 - 97. doi: 10.1016/S0140-6736(99)05190-9

[620] Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of Influenza Vaccine in Health Care Professionals. JAMA. 1999; 281(10): 908 - 913. doi: 10.1001/jama.281.10.908

[621] Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial. Arch Intern Med. 1996; 156(14): 1546 - 1550.

[622] Simpson CR, Lone NI, Kavanagh K, et al. Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. BMJ Open. 2017; 7(2): e014200. doi: 10.1136/bmjopen-2016-014200

[623] Rondy M, El Omeiri N, Thompson MG, et al. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies. J Infect. 2017; 75(5): 381 - 394. doi: 10.1016/j.jinf.2017.09.010

[624] Darvishian M, van den Heuvel ER, Bissielo A, et al. Effectiveness of seasonal influenza vaccination in community-dwelling elderly people: an individual participant data meta-analysis of test-negative design case-control studies. Lancet Respir Med. 2017; 5(3): 200 - 211. doi: 10.1016/S2213-2600(17)30043-7

[625] Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med. 2015; 13(1): 53. doi: 10.1186/s12916-015-0295-6

[626] Demurtas J, Celotto S, Beaudart C, et al. The efficacy and safety of influenza vaccination in older people: An umbrella review of evidence from meta-analyses of both observational and randomized controlled studies. Ageing Res Rev. 2020; 62101118. doi: 10.1016/j.arr.2020.101118

[627] Smith SA, Poland GA. Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care. 2000; 23(1): 95 - 108. doi: 10.2337/diacare.23.1.95

[628] Чучалин А.Г., Брико Н.И., Авдеев С.Н. и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019; 29(1): 19 - 34. doi: 10.18093/0869-0189-2019-29-1-19-34

[629] Tin Tin Htar M, Stuurman AL, Ferreira G, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS One. 2017; 12(5): e0177985. doi: 10.1371/journal.pone.0177985

[630] Isturiz R, Webber C. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults. Hum Vaccin Immunother. 2015; 11(7): 1825 - 1827. doi: 10.1080/21645515.2015.1043502

[631] Webber C, Patton M, Patterson S, et al. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Vaccine. 2017; 35(9): 1266 - 1272. doi: 10.1016/j.vaccine.2017.01.032

[632] LeBlanc JJ, ElSherif M, Ye L, et al. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN. Vaccine. 2019; 37(36): 5466 - 5473. doi: 10.1016/j.vaccine.2019.05.003

[633] Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal adults 60 - 64 years of age. Vaccine. 2014; 32(20): 2364 - 2374. doi: 10.1016/j.vaccine.2014.02.002

[634] Paradiso PR. Pneumococcal Conjugate Vaccine for Adults: A New Paradigm. Clin Infect Dis. 2012; 55(2): 259 - 264. doi: 10.1093/cid/cis359

[635] Feld J, Janssen A, Abbas Z, et al. Глобальные Практические Рекомендации Всемирной Гастроэнтерологической Организации. Гепатит B. World Gastroenterology Organisation, 2015

[636] Van Den Ende C, Marano C, Van Ahee A, et al. The immunogenicity and safety of GSK's recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience. Expert Rev Vaccines. 2017; 16(8): 811 - 832. doi: 10.1080/14760584.2017.1338568

[637] Van Der Meeren O, Peterson JT, Dionne M, et al. Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus. Hum Vaccin Immunother. 2016; 12(8): 2197 - 2203. doi: 10.1080/21645515.2016.1164362

[638] Elhanan E, Boaz M, Schwartz I, et al. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-VacTM, as compared to Engerix B, among vaccine and vaccine non-responder dialysis patients. Clin Exp Nephrol. 2018; 22(1): 151 - 158. doi: 10.1007/s10157-017-1416-7

[639] Van Der Meeren O, Crasta P, Cheuvart B, et al. Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis. Hum Vaccin Immunother. 2015; 11(7): 1725 - 1728. doi: 10.1080/21645515.2015.1039758

[640] Keating GM, Noble S. Recombinant Hepatitis B Vaccine (Engerix-B??). Drugs. 2003; 63(10): 1021 - 1051. doi: 10.2165/00003495 - 200363100-00006

[641] Gregory JM, Slaughter JC, Duffus SH, et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Diabetes Care. 2021; 44(2): 526 - 532. doi: 10.2337/dc20-2260

[642] Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584(7821): 430 - 436. doi: 10.1038/s41586-020-2521-4

[643] Методические рекомендации (Письмо Министерства здравоохранения Российской Федерации от 21 января 2021 г. N 1/И/1-333)

[644] Приказ Министерства здравоохранения РФ от 9 декабря 2020 г. N 1307н "О внесении изменений в календарь профилактических прививок по эпидемическим показаниям, утвержденный приказом Министерства здравоохранения Российской Федерации от 21 марта 2014 г. N 125н

[645] Rogliani P, Chetta A, Cazzola M, et al. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. Vaccines. 2021; 9(3): 227. doi: 10.3390/vaccines9030227

[646] Logunov DY, Dolzhikova I V, Shcheblyakov D V, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397(10275): 671 - 681. doi: 10.1016/S0140-6736(21)00234-8

[647] COVID-19 vaccines, http: //www.ncbi.nlm.nih.gov/pubmed/33355732 (2006)

[648] Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021; 397(10275): 642 - 643. doi: 10.1016/S0140-6736(21)00191-4

[649] Бакулин И.Г., Жданов К.В., Дроздова Л.Ю., и др. Возможности вакцинопрофилактики инфекционных заболеваний у взрослого населения. Профилактическая и клиническая медицина. 2020(4(77)): 4 - 19. doi: 10.47843/2074-9120_2020_4_4

[650] Balakrishnan VS. The arrival of Sputnik V. Lancet Infect Dis. 2020; 20(10): 1128. doi: 10.1016/S1473-3099(20)30709-X

[651] COVID research: a year of scientific milestones. Nature. Epub ahead of print 5 May 2021. DOI: 10.1038/d41586-020-00502-w

[652] Шестакова М.В., Викулова О.К., Исаков М.А. и др. Сахарный диабет и COVID-19: анализ клинических исходов по данным регистра сахарного диабета Российской Федерации. Проблемы эндокринологии. 2020; 66(1): 35 - 46. doi: 10.14341/probl12458

[653] Ho C-H, Jaw F-S, Wu C-C, et al. The Prevalence and the Risk Factors of Testosterone Deficiency in Newly Diagnosed and Previously Known Type 2 Diabetic Men. J Sex Med. 2015; 12(2): 389 - 397. doi: 10.1111/jsm.12777

[654] Ding EL, Song Y, Malik VS, et al. Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes. JAMA. 2006; 295(11): 1288 - 1299. doi: 10.1001/jama.295.11.1288

[655] Kapoor D, Aldred H, Clark S, et al. Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007; 30(4): 911 - 917. doi: 10.2337/dc06-1426

[656] Tajar A, Huhtaniemi IT, O'Neill TW, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012; 97(5): 1508 - 1516. doi: 10.1210/jc.2011-2513

[657] Brand JS, Rovers MM, Yeap BB, et al. Testosterone, Sex Hormone-Binding Globulin and the Metabolic Syndrome in Men: An Individual Participant Data Meta-Analysis of Observational Studies. PLoS One. 2014; 9(7): e100409. doi: 10.1371/journal.pone.0100409

[658] Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А. и др. Проект клинических рекомендаций "Синдром гипогонадизма у мужчин". Ожирение и метаболизм. 2021; 18(4): 496 - 507. doi: 10.14341/omet12817